

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Dynamics and Determinants of HPV Infection: The Michigan HPV and Oropharyngeal Cancer (M-HOC) Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021618
Article Type:	Protocol
Date Submitted by the Author:	15-Feb-2018
Complete List of Authors:	Eisenberg, Marisa; University of Michigan, Ann Arbor, Epidemiology Campredon, Lora; University of Michigan, Ann Arbor, Epidemiology Brouwer, Andrew; University of Michigan, Ann Arbor, Epidemiology Walline, Heather; University of Michigan, Ann Arbor, Otolaryngology Marinelli, Brittany; University of Michigan, Ann Arbor, Otolaryngology Lau, Yan; University of Michigan, Ann Arbor, Epidemiology Thomas, Trey; University of Michigan, Ann Arbor, Otolaryngology Delinger, Rachel; University of Michigan, Ann Arbor, Epidemiology Sullivan, Taylor; University of Michigan, Ann Arbor, Epidemiology Yost, Monica; University of Michigan, Ann Arbor, Epidemiology Goudsmit, Christine; University of Michigan, Ann Arbor, Otolaryngology Carey, Thomas; University of Michigan, Ann Arbor, Otolaryngology Meza, Rafael; University of Michigan, Epidemiology
Keywords:	Human Papillomavirus, Oropharyngeal cancer, Longitudinal study, Sexual behavior, Oral rinse

SCHOLARONE™
Manuscripts

Only

Dynamics and Determinants of HPV Infection: The Michigan HPV and Oropharyngeal Cancer (M-HOC) Study

Marisa C. Eisenberg^{*,†}, Lora P. Campredon[†], Andrew F. Brouwer[†],
Heather M. Walline[‡], Brittany M. Marinelli[‡], Yan Kwan Lau[†], Trey B. Thomas[‡],
Rachel L. Delinger[†], Taylor S. Sullivan[†], Monica L. Yost[†],
Christine M. Goudsmit[‡], Thomas E. Carey[‡], and Rafael Meza^{*,†}

† Department of Epidemiology, University of Michigan, Ann Arbor,

‡ Department of Otolaryngology, University of Michigan, Ann Arbor

* Co-corresponding authors, marisae@umich.edu, rmeza@umich.edu

1415 Washington Heights, 4667 SPH I

Ann Arbor, MI 48109-2029

Phone: (734) 763-2991

Keywords: Human papillomavirus, Sexual Behavior, Surveys and Questionnaires, Cervicovaginal Swab

Word count: 2746

Abstract

Introduction: Human papillomavirus (HPV) is the primary cause of cervical and other anogenital cancers, and is also associated with head and neck cancers. Incidence of HPV-related oropharyngeal squamous cell cancers (OPSCCs) is increasing, and HPV-related OPSCCs have surpassed cervical cancer as the most common HPV-related cancer in the U.S. Given the multisite nature of HPV, there is strong interest in collecting data from both genital and oral sites, as well as associated data on social and sexual behaviors. The overarching goal of this study is to evaluate patterns of oral HPV infection incidence and clearance and their relationship to sexual history and long-term OPSCC risk.

Methods and Analysis: Participants are recruited from two populations: college students at a large public university and general population from the surrounding area. At the first study visit participants will complete a detailed sexual history, health, and behavior questionnaire. Follow-up visits will occur every 3–4 months over 3 years, when participants will complete an abbreviated questionnaire. All participants will provide a saliva sample at each visit, and eligible women may provide a cervical self-swab. Genetic material isolated from specimens will be tested for 15 high-risk and 3 low-risk HPV types. Statistical analyses will examine outcome variables including HPV prevalence, incidence, persistence, and clearance. Logistic regression models will be used to estimate odds ratios and 95% confidence intervals for associations between the outcomes of interest and demographic/behavioral variables collected in the questionnaires. The longitudinal HPV infection data and detailed sexual history data collected in the questionnaires will allow us to develop

individual-based network models of HPV transmission and will be used to parameterize multi-scale models of HPV-related OPSCC carcinogenesis.

Ethics and Dissemination: This study has been approved by the University of Michigan Institutional Review Board. All participants are consented in person by trained study staff.

Article Summary

Strengths and Limitations of this study

- Longitudinal design with 3–4 study visits per participant per year allows for analysis of incidence, persistence, and clearance of oral HPV.
- Collection of both oral and cervical samples allows for comparison of infections across sites.
- Low prevalence of high-risk oral HPV may limit our ability to connect HPV infection dynamics to demographic, sexual, and behavioral variables.

Introduction

Infectious disease agents account for approximately 20% of cancers worldwide [1]. The human papillomavirus (HPV) is the primary cause of cervical and most anogenital cancers, as well as an increasing fraction of head and neck cancers [2, 3]. Indeed, incidence of HPV-related oropharyngeal squamous cell cancers (OPSCCs) is increasing [4–7], and HPV-related OPSCCs have surpassed cervical cancer as the most common HPV-related cancer in the US [3]. At the University of Michigan Cancer Center, over 80% of OPSCC patients have high-risk HPV detected in their cancers [8]. Although many HPV infections are benign, high-risk HPV infections can disrupt several key cancer regulation pathways, including particularly those involving tumor suppressors p53 and pRb [9, 10].

The underlying reasons behind the significant rise in HPV-related OPSCC rates in the U.S. are unclear. From a prevention perspective, addressing HPV-related OPSCC begins with an understanding of the epidemiology of the virus, both in the oral cavity and more broadly. Estimates from the National Health and Nutrition Examination survey (NHANES) estimate oral HPV prevalence in the U.S. to be about 11–12% for men and 3–4 % for women [11–14]. While studies are increasingly treating HPV as a multisite disease, the mechanisms underlying the

1
2
3 relationship between oral, genital, and anal HPV infections are not understood, although
4 autoinoculation is increasingly implicated [15, 16]. The HPV vaccine further complicates the
5 epidemiological picture: HPV vaccination is expected to have an impact on the rates of oral HPV
6 incidence, at least for those genotypes included in the vaccine [12, 17]. Countries with more
7 aggressive vaccination campaigns, such as Australia, have already seen a reduction in HPV-
8 related genital warts [18, 19]. It remains to be seen whether HPV vaccination will ultimately
9 reduce the incidence and mortality of HPV-related head and neck cancers.
10
11

12
13
14 Many open questions remain regarding oral HPV transmission epidemiology, infection and
15 persistence, the mechanisms of HPV-related HN carcinogenesis, and the connection between
16 the ongoing oral HPV epidemic and the rising OPSCC incidence. The knowledge gaps
17 surrounding the mechanisms and epidemiology of HPV in the oral cavity hamper our ability to
18 develop more effective measures to prevent oral HPV infections and, in turn, reduce the burden
19 of head and neck cancers. Prevalence studies can only draw associations between the burden
20 and probable risk factors. Thus, longitudinal studies with frequent testing and assessment of
21 recent sexual behavior are needed to understand HPV transmission, persistence, and clearance
22 and to associate these events with certain behaviors. Here, we describe the methods, study
23 design, and initial study population characteristics of a longitudinal study of oral HPV incidence,
24 clearance, and related sexual behaviors, the Michigan HPV and Oropharyngeal Cancer (M-
25 HOC) Study and its cervical HPV sub-study. Our research will contribute to a better
26 understanding of the complex factors affecting patterns of HPV infection. This study will inform
27 predictive and mechanistic models and develop effective prevention strategies for OPSCC and
28 other HPV-related cancers.
29
30
31
32
33
34
35
36
37
38
39
40

41 **Methods and Analysis**

42 ***Objective***

43
44
45 The overarching goal of this study is to evaluate patterns of oral HPV infection incidence and
46 clearance and their relationship to sexual history and sexual behaviors. Participants are
47 recruited to the study from two populations: college students at the University of Michigan (UM)
48 (a large public university) and the general population of the surrounding area. As a secondary
49 goal, we will also compare HPV infection patterns in the oral and cervical sites as part of a sub-
50 study examining cervical HPV infections.
51
52
53
54
55
56
57
58
59
60

Subject enrollment and consent

Here, we describe the process for subject enrollment and consent (diagrammed in Figure 1).

Identification of Study Subjects. Participants are continuously recruited by one of three methods.

1) Advertisement: we place recruitment announcements in UM health clinics and area community sites (e.g. libraries, coffee shops, bus stops), as well as on UM clinical research volunteer's website (www.umclinicalstudies.org). In this method, individuals who are potentially interested in participating in the study contact the study coordinator to determine eligibility. 2) Screening clinics: we approach participants of the UM health system free throat cancer screening clinic to invite eligible participants to join the study. 3) Student residence halls: once per year, we set up information tables in or near UM residence halls and invite eligible students to join the student.

Eligibility Criteria. Volunteers are considered for enrollment if they

- Are age 18 or older,
- Do not have a history of head or neck cancer,
- Are willing to return for a follow up every 3–4 months over 3 years,
- And are able and willing to provide written informed consent.

To participate in the optional cervical sub-study, participants must additionally

- Have female genitals,
- Not be pregnant,
- And not be menstruating at the time of the study visit.

Consent. We document informed consent for all willing and eligible participants before enrollment in the study. Separate, additional consent is obtained prior to enrollment in the cervical sub-study. All study subjects are given the opportunity to consent to storage of residual specimens collected in this study for future research purposes. Specimens collected from subjects who do not consent to specimen banking will be destroyed after completion of the analyses of this study.

Enrollment targets. We plan to enroll up to 1,000 individuals to participate over the course the first 5 years of this study. This study has been in active recruitment since April 2015 and has thus far (as of November 2017) enrolled 341 individuals who have completed the baseline questionnaire. Of these, 220 have completed at least one follow-up visit.

1
2
3 **Figure 1:** Flow diagram for the study detailing recruitment methods, visit structure (baseline and
4 followups), and the cervical sub-study.
5
6
7

8 9 **Data collection**

10
11 We administer surveys and collect biological specimens as described below.

12
13 *Social and Sexual Behavior Survey.* All study participants complete a comprehensive
14 questionnaire at the baseline visit and an abbreviated questionnaire at all subsequent visits. The
15 questionnaire consists of questions related to demographic information; alcohol, cigarette, cigar,
16 tobacco, and other drug use; and sexual practices, sexual history, sexual healthcare, general
17 health, and history of sexually transmitted infections (STIs). The baseline questionnaire collects
18 a complete sexual history, with subsequent follow up visits providing more recent information
19 and updates. The questions regarding sexual behaviors and history are designed to provide
20 detailed information about the timing of different sexual partnerships and sexual practices in
21 each sexual partnership and form a longitudinal, egocentric sexual network data set. Table 1
22 details the categories and numbers of questions given in both the baseline and follow-up
23 surveys. The questionnaire is administered electronically via Qualtrics in a quiet, private room.
24 Participants are asked to enter their unique study identification number at the beginning of the
25 questionnaire. Participants are free to skip or otherwise not answer any question.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Categories and numbers of questions asked in MHOC study baseline and follow-up questionnaire.

Question category	Number of questions	
	Baseline	Follow-up
Demographic	8	5
Oral health and cancer	5	5
STI testing and diagnosis	17	12
Sexual health and vaccinations	25	16
Sexual behavior	70	6
Sexual partners	22	18
Substance use	20	16

Oral Specimen Collection. Two mL of saliva and oral rinse specimen are collected at each visit (i.e. baseline and every 3-4 months for 3 years) using Oragene RE-100 kits [20]. Participants may use a sweetener or candy to stimulate saliva production if needed.

In the initial phase of the study, we tested several alternative saliva collection methods: Scope-brand mouthwash (administered as in NHANES [21]), and two commercially available kits developed for detection of DNA and RNA in saliva, the OM-505 (suitable for DNA, stable for weeks at room temperature) and RE-100 (designed to protect RNA, stable for 60 days at room temperature) [20, 22]. We were able to detect DNA from saliva in all three methods but were only able to reliably recover RNA from the RE-100 kit sample. We selected the RE-100 kits for use in the study so that we could isolate both DNA and RNA from a single sample.

Cervical swab collection. Participants fulfilling the eligibility criteria are given the option at each study visit to provide a self-collected cervical swab sample using a HerSwab [23] in addition to the oral specimen. Participants self-administer the swab by inserting the tip of the HerSwab into the vagina; turning the crank so that the brush is fully extended; removing the swab; turning the crank the opposite direction to retract the brush back into the tip; and placing the HerSwab into a provided resealable plastic bag. The participants are provided with the printed, graphical instructions designed by the manufacturer and collect their sample in a restroom. Staff facilitating the study are available to review the procedure and answer any participant questions.

Cervical swab acceptability survey. All study participants who provide a cervical sample complete a questionnaire after each cervical self-collection that asks about comfort, ease-of-use, and subjective assessment of the self-collection procedure [24]. The questionnaire is administered electronically via Qualtrics.

Follow-up visit schedule

Participants are followed for up to three years after their baseline visit, for a total of up to 12 study visits. The study prioritizes longitudinal follow-up over regular follow-up, but strives to achieve both. Therefore, if participants miss a follow-up visit, they are not excluded and instead continue the study when next available. This protocol facilitates research in the student population, as students are often gone for extended periods of time on scheduled breaks.

Sample processing and analysis

Sample processing and DNA extraction differs for oral and cervical samples, but DNA analysis is the same for both kinds of samples.

Oral sample processing. DNA isolation from saliva samples is performed by first splitting the sample in half, half for DNA and half for RNA. The saliva is heated to 50°C for 60 minutes, 1/25th volume of prepIT-L2P (DNA Genotek) is added. Sample is incubated for 10 minutes at 4°C and spun for 20 minutes at 4100 rpm. After the supernatant is added to equal volumes of 95% ethanol to precipitate the DNA. The DNA is pelleted, washed with 200 μ L of 70% ethanol and dried. The DNA pellet is rehydrated with Tris-EDTA buffer and quantified with picogreen (Invitrogen P11496) or the QuBit (Invitrogen Q32850). RNA is isolated from samples that have tested positive for HPV DNA. RNA isolation from saliva samples is performed using the Oragene RNA isolation method according to the manufacturer's instruction which includes QIAgen's RNeasy Micro Kit (74004). In short, the samples are heated to 50°C for 60 minutes, 95°C for 15 minutes, 20 μ L neutralization solution is added. Samples then are incubated on ice for 10 minutes followed by the RNeasy Kit protocol. The RNA is then are converted to cDNA for further testing. The cDNA synthesis is preformed using Invitrogen's Superscript III protocol and reagents (18080-044).

Cervical sample processing. After collection, the HerSwab is soaked and swished vigorously, for one minute each, in 20 mL of ThinPrep solution. The 20 mL solution is then split evenly into two 15 mL nuclease-free conical tubes—one for RNA processing and one for DNA—and the tube for RNA is centrifuged. The pellet for RNA use is resuspended in RNAlater for isolation and later study. DNA and RNA processing is the same as above. For RNA isolation, the cells in RNAlater are pelleted by centrifugation and RNA is isolated using the RNeasy as described above. Qiagen reagents are used for DNA isolation. The cells in the ThinPrep sample are pelleted, resuspended in cell lysis buffer, incubated with Proteinase k, treated with protein precipitation

1
2
3 buffer, vortexed vigorously, pelleted and placed on ice for 10 minutes. The supernatant is
4 transferred to isopropanol in glycogen solution mixed, and the DNA pellet is washed twice with
5 cold ethanol, re-hydrated in hydration solution and dissolved at 65°C, and DNA is quantified with
6 picogreen or QuBit.
7
8
9

10 *DNA analysis.* DNA and cDNA samples are assayed using a previously described, highly-
11 sensitive method [8]. Briefly, multiplex competitive PCR amplification of the heterogenous E6
12 region of 15 discrete high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73) and 3
13 low-risk (6, 11, 90) HPV types is performed, followed by probe-specific single base extension.
14 Extension products are loaded onto a matrix silicon chip array and separated by size using
15 matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectroscopy,
16 allowing detection of any HPV types present in the sample.
17
18
19
20
21
22

23 ***Statistical analysis***

24
25
26 Outcomes of interest include, but are not limited to, HPV prevalence, incidence, persistence,
27 and clearance. Covariates of interest include, but are not limited to, sex, age, student status,
28 HIV-status, sexual orientation, HPV vaccine status, circumcision status, number of vaginal, oral,
29 and anal sexual partners, timing and nature of recent sexual activity, use of sexual protection,
30 and substance use. Demographic and sexual behavior differences among subpopulations will
31 be considered.
32
33
34
35

36 Logistic regression models will be used to estimate odds ratios and 95% confidence intervals for
37 associations between the outcomes of interest and the demographic/behavioral variables.
38 Variables that are significant in univariate analysis or are considered to be relevant based on a
39 priori knowledge will be evaluated in multiple logistic regression models. Cox regression models
40 will be used to investigate the effect of covariates on clearance. Analyses will be performed in
41 SAS or R statistical softwares.
42
43
44
45

46 ***Modeling analysis***

47
48
49 The longitudinal HPV infection data and detailed sexual partner and sexual history data
50 collected in the questionnaires will allow us to develop individual-based network models of HPV
51 transmission. While the data from the study are necessarily egocentric (i.e. we cannot link
52 partners reported by participants to any specific individual in or out of the study to form a full
53
54
55
56
57
58
59
60

1
2
3 sexual network), they can nonetheless be used to directly parameterize simulation models of
4 transmission. The models we develop can match the timing of partner switching, numbers of
5 partners, and type of sexual contact, as well as a range of behavioral and demographic
6 covariates as well as HPV infections and clearance times. This will allow us to generalize our
7 statistical model findings to different populations and to examine counterfactual scenarios of
8 alternative HPV vaccine coverage levels. Similar models have been developed for other studies,
9 both for sexually transmitted infections and other infectious diseases [25–30]. This study is
10 designed to specifically inform such modeling analyses.
11
12
13
14
15
16
17

18 **Ethics**

19
20
21 The MHOC study was approved by the University of Michigan Institutional Review Board on
22 August 26, 2014 (IRB # HUM00090326). This study was deemed to not require additional safety
23 monitoring beyond the monitoring of the institutional review board. All study staff interacting with
24 participants and participant data complete the University of Michigan Program for Education and
25 Evaluation in Responsible Research and Scholarship (PEERRS) prior to beginning the project
26 [31]. Informed consent is obtained from each participant by the study coordinator and PEERRS
27 certified research assistants.
28
29
30
31
32
33
34

35 **Discussion**

36
37
38 The knowledge gained from this study will contribute to the field of HPV research, and will be
39 disseminated via peer reviewed publications and presentations at national and international
40 conferences. This study will provide improved estimates of HPV clearance rates in the oral
41 cavity, due to the short follow-up times, and will also allow us to examine how HPV clearance is
42 affected by a range of factors, including coinfection with multiple HPV types. More broadly, this
43 study will improve our understanding of the relationships between behavior patterns and HPV,
44 helping to elucidate how sexual behaviors, numbers of partners, and other behaviors (e.g.
45 alcohol and substance use) relate to HPV infection patterns. Additionally, this study will provide
46 detailed data on HPV transmission in the college student population—a key population who are
47 also seeing changing vaccination patterns as HPV vaccine coverage improves. This will allow
48 us to further examine the impact of HPV vaccination on the incidence and prevalence of a range
49 of vaccine types (both those covered by the vaccine and others). The study questionnaire and
50
51
52
53
54
55
56
57
58
59
60

1
2
3 longitudinal design also are also useful in developing sexual network models of transmission,
4 which will allow us to examine alternative vaccination strategies and generalize to other
5 populations.
6
7

8 9 ***Limitations and Strengths***

10
11
12 Because oral HPV prevalence in the United States is relatively low (prevalence of high-risk oral
13 HPV among adults 18–69 was 4.0% in 2011–2014: 6.8% in men and 1.2% in women [14]),
14 there is a risk that number of HPV positive samples in the study will be low, limiting our abilities
15 to draw inference between HPV infection and the demographic and behavioral variables of the
16 participant.
17
18

19
20 Instead of identifying risk factors through associations in cross-sectional prevalence analyses,
21 we will use a longitudinal approach with frequent oral and cervical HPV testing and updated
22 detailed sexual behavior questionnaires. This will allow for understanding not only prevalence of
23 HPV but also incidence, persistence, and clearance. Some studies have also adopted a
24 longitudinal approach (e.g. [32–36]), but many have had long times between follow-up or have
25 focused only on sex or only on genital infection sites. In the MHOC study, we use short follow-
26 up times, with 3–4 visits per participant per year. We focus primarily on oral infection in both
27 men and women but also collect cervical samples to assess multisite infections.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author's contributions

The study was conceptualized and funding was obtained by MCE, TEC, and RM. Methodology and original protocols were developed by MCE, LPC, AFB, HMW, BMM, YKL, TBT, RLD, CMG, TEC, and RM. Project administration is managed by LPC and YKL. MCE, LPC, AFB, HMW, BMM, YKL, CG, TEC, and RM are responsible for supervision of study implementation, staff, and students.

The original draft was prepared by MCE with the assistance of LPC, TSS, and MLY. Review and editing was completed by MCE, LPC, AFB, HMW, BMM, YKL, TEC, and RM.

Funding statement

This work was supported by National Institutes for Health Grant U01CA182915, the University of Michigan MCubed program, a pilot grant from University of Michigan Comprehensive Cancer Center's Cancer Epidemiology & Prevention program (supported by the National Cancer Institute of the National Institutes of Health grant P30CA046592), and the Michigan Institute for Clinical and Health Research (NIH grant UL1TR000433).

Acknowledgments

We would like to thank Professors Carol Bradford, Paul Hoff, Norm Hogikyan, Trachette Jackson, James Koopman, Kelly Malloy, John McHugh, Erin McKean, Mark Prince, Jamie Riddell, Laura Rozek, Andrew Shuman, Matthew Spector, Jeffrey Stanley, Jeremy Taylor, Francis Worden, and Gregory Wolf, for their helpful comments, advice, and support.

We also thank our collaborators, study and laboratory staff, and students: Miranda West, Thankum Nair, Lisa Petersen, Sheila Terrones, Chad Brenner, Emily Bellile, Justin Bell, Tori Melandez, and Eliyas Asfaw, Christian Alvarez, Kristin Bevilacqua, Pian Pian Cao, Alanna Clark, Jesse Contreras, Rachel Delinger, Greg Foakes, Anna Gottschlich, Manila Hada, Christina Hanson, Nadine Jawad, Bala Naveen Kakaraparthi, Alexandra Kalabat, Jung Woo Lee, Jodi McCloskey, Ivan Montoya, Anna Morris, Chinmay Pandit, Derrick Sund, Kayla Stanek, Peter Tortora, Taylor Vandenberg, and Lucy Yang. We would like to thank all of our staff and our study participants, without whom this study would not have been possible.

Competing interests statement

All authors declare no conflicts of interest.

For peer review only

References

- [1] Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—Part B: biological agents. *The Lancet Oncology*. 2009;10(4):321–322. Available from: [http://dx.doi.org/10.1016/S1470-2045\(09\)70096-8](http://dx.doi.org/10.1016/S1470-2045(09)70096-8).
- [2] Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine*. 2012 nov;30 Suppl 5:F34–54. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23199965>.
- [3] Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. *Journal of the National Cancer Institute*. 2013;105(3):175–201. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3565628&tool=pmcentrez&rendertype=abstract>.
- [4] Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *Journal of Clinical Oncology*. 2008;26(4):612–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18235120>.
- [5] Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *Journal of Clinical Oncology*. 2011;29(32):4294–301. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3221528&tool=pmcentrez&rendertype=abstract>.
- [6] Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *Journal of Clinical Oncology*. 2013 dec;31(36):4550–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24248688>.
- [7] Chaturvedi AK, D'Souza G, Gillison ML, Katki HA. Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. *Oral Oncology*. 2016;60:61–67. Available from: <http://www.sciencedirect.com/science/article/pii/S136883751630080X>.

- 1
2
3 [8] Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-Risk
4 Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers.
5 JAMA Otolaryngology–Head & Neck Surgery. 2013;139(12):1320.
6 Available from: <http://archotol.jamanetwork.com/article.aspx?doi=10.1001/jamaoto.2013.5460>.
7
8 [9] Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-
9 cycle of human papillomaviruses. Vaccine.
10 2012 nov;30 Suppl 5:F55–70. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23199966>.
11
12 [10] McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papillomaviruses.
13 Virus Research. 2009;143(2):195–208.”
14
15 [11] Gillison ML, Broutian T, Pickard RKL, Tong Zy, Xiao W, Kahle L, et al. Prevalence of oral
16 HPV infection in the United States, 2009-2010. Journal of the American Medical Association.
17 2012;307(7):693–703. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22282321>.
18
19 [12] Brouwer AF, Eisenberg MC, Carey TE, Meza R. Trends in HPV cervical and
20 seroprevalence and associations between oral and genital infection and serum antibodies in
21 NHANES 2003-2012. BMC Infectious Diseases. 2015 dec;15(1):575. Available from:
22 <http://www.biomedcentral.com/1471-2334/15/575>.
23
24 [13] Sonawane K, Suk R, Chiao EY, Chhatwal J, Qiu P, Wilkin T, et al. Oral Human
25 Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With
26 Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Annals of Internal Medicine.
27 2017; Available from: <http://annals.org/aim/article/2657698/>
28 oral-human-papillomavirus-infection-differences-prevalence-between-sexes-concordance-
29 genital.
30
31 [14] McQuillan G, Kruszon-moran D, Markowitz LE, Unger ER, Paulose-ram R. Prevalence
32 of HPV in Adults Aged 18–69: United States,
33 2011–2014. NCHS Data Brief. 2017;280. Available from:
34 <https://www.cdc.gov/nchs/products/databriefs/db280.htm>.
35
36 [15] Pamnani SJ, Nyitray AG, Abrahamsen M, Rollison DE, Villa LL, Lazcano-Ponce E, et al.
37 Sequential Acquisition of Anal Human Papillomavirus (HPV) Infection Following Genital
38 Infection among Men Who Have Sex with Women: The HPV Infection in Men (HIM) Study.
39 Journal of Infectious Diseases. 2016;214(8):1180–1187.
40
41 [16] Ranjeva S, Baskerville EB, Dukic V, Villa L, Lazcano-Ponce E, Giuliano AR, et al.
42 Recurring infection with ecologically distinct human papillomavirus (HPV) types explains high
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 prevalence and diversity. bioRxiv. 2017; Available from: <https://www.biorxiv.org/content/early/2017/08/23/179341>.

4
5
6
7 [17] Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV
8 After Introduction of the Vaccination Program
9 in the United States. *Pediatrics*. 2016;137(3):1–9. Available from:
10 <http://www.ncbi.nlm.nih.gov/pubmed/26908697>.

11
12
13 [18] Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich aE, et al. Genital warts in
14 young Australians five years into national human papillomavirus vaccination programme:
15 national surveillance data. *BMJ*. 2013;346:2032–2032. Available from: <http://www.bmj.com/cgi/doi/10.1136/bmj.f2032>.

16
17
18
19
20 [19] Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing
21 decline in genital warts among young heterosexuals 7 years after the Australian human
22 papillomavirus (HPV) vaccination programme. *Sexually Transmitted Infections*.
23 2015;91(3):214–219. Available from: <http://sti.bmj.com/lookup/doi/10.1136/sextrans-2014-051813>.

24
25
26
27
28 [20] DNA Genotek, Inc. Oragene-RNA (RE-100); 2017. Available from:
29 <http://www.dnagenotek.com/US/products/RE100.html>.

30
31
32 [21] Centers for Disease Control and Prevention. National Health and Nutrition Examination
33 Survey (NHANES): HPV rinse; 2009.
34 Available from: <https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/manuals/HPV.pdf>.

35
36
37 [22] DNA Genotek, Inc. OMNIgene-ORAL (OM-505); 2017. Available from:
38 <http://www.dnagenotek.com/US/products/OM505.html>.

39
40
41 [23] Eve Medical. Eve Medical products: HerSwab; 2017. Available from: <http://www.eve-medical.com/products>.

42
43
44
45 [24] Gottschlich A, Rivera-Andrade A, Grajeda E, Alvarez C, Montano CM, Meza R.
46 Acceptability of Human Papillomavirus SelfSampling for Cervical Cancer Screening in an
47 Indigenous Community in Guatemala. *Journal of Global Oncology*. 2017;3(5):444– 454.
48 Available from: <https://doi.org/10.1200/JGO.2016.005629>.

49
50
51
52 [25] Petrie JG, Eisenberg MC, Ng S, Malosh RE, Han Lee K, Ohmit SE, et al. Application of
53 an Individual-Based Transmission Hazard Model for Estimation of Influenza Vaccine
54 Effectiveness in a Household Cohort. *American journal of epidemiology*;

- 1
2
3 [26] Aiello AE, Simanek AM, Eisenberg MC, Walsh AR, Davis B, Volz E, et al. Design and
4 methods of a social network isolation study for reducing respiratory infection transmission: The
5 eX-FLU cluster randomized trial. *Epidemics*. 2016;15:38–55.
6
7
8 [27] Fan K, Eisenberg M, Walsh A, Aiello A, Heller K. Hierarchical graph-coupled hmms for
9 heterogeneous personalized health data. In: *Proceedings of the 21th ACM SIGKDD*
10 *International Conference on Knowledge Discovery and Data Mining*. ACM; 2015. p. 239–248.
11
12
13 [28] Kaplan EH, Heimer R. HIV prevalence among intravenous drug users: model-based
14 estimates from New Haven's legal needle exchange. *JAIDS Journal of Acquired Immune*
15 *Deficiency Syndromes*. 1992;5(2):163–169.
16
17
18 [29] Sloom PM, Ivanov SV, Boukhanovsky AV, van de Vijver DA, Boucher CA. Stochastic
19 simulation of HIV population dynamics through complex network modelling. *International*
20 *Journal of Computer Mathematics*. 2008;85(8):1175–1187.
21
22
23 [30] Cohen T, Colijn C, Finklea B, Murray M. Exogenous re-infection and the dynamics of
24 tuberculosis epidemics: local effects in a network model of transmission. *Journal of The Royal*
25 *Society Interface*. 2007;4(14):523–531.
26
27
28 [31] University of Michigan. Responsible Conduct of Research (RCR) Training; 2017.
29 Available from: <http://research-compliance.umich.edu/responsible-conduct-research-rcr-training>.
30
31
32 [32] Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal
33 papillomavirus infection in young women. *The New England Journal of Medicine*.
34 1998;338(7):423–8. Available from: <http://www.nejm.org/doi/full/10.1056/NEJM199802123380703><http://www.ncbi.nlm.nih.gov/pubmed/9459645>.
35
36
37 [33] Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, D'esy M, et al.
38 Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women
39 from a high-risk area for cervical cancer. *Journal of Infectious Diseases*. 1999 nov;180(5):1415–
40 23. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10515798>.
41
42
43 [34] Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al.
44 Determinants of clearance of human papillomavirus infections in Colombian women with normal
45 cytology: a population-based, 5-year follow-up study. *American Journal of Epidemiology*. 2003
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sep;158(5):486–94. Available from: <http://aje.oupjournals.org/cgi/doi/10.1093/aje/kwg171>
4 <http://www.ncbi.nlm.nih.gov/pubmed/12936904>.

5
6
7 [35] Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al.
8 Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the
9 Hawaii HPV Cohort Study. *The Journal of Infectious Diseases*.
10 2010;201(9):1331–9. Available from:
11 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2851490&tool=](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2851490&tool=pmcentrez&rendertype=abstract)
12 [pmcentrez&rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2851490&tool=pmcentrez&rendertype=abstract).

13
14
15 [36] Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and
16 clearance of genital human papillomavirus infection in men (HIM): a cohort study. *Lancet*.
17 2011;377(9769):932–40. Available from: [http://www.pubmedcentral.nih.](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3231998&tool=pmcentrez&rendertype=abstract)
18 [gov/articlerender.fcgi?artid=3231998&tool=pmcentrez&rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3231998&tool=pmcentrez&rendertype=abstract).




Figure 1: Flow diagram for the study detailing recruitment methods, visit structure (baseline and followups), and the cervical sub-study.

361x140mm (300 x 300 DPI)

Peer review only

BMJ Open

Dynamics and Determinants of HPV Infection from the Michigan HPV and Oropharyngeal Cancer (M-HOC) Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021618.R1
Article Type:	Protocol
Date Submitted by the Author:	24-May-2018
Complete List of Authors:	Eisenberg, Marisa; University of Michigan, Ann Arbor, Epidemiology Campredon, Lora; University of Michigan, Ann Arbor, Epidemiology Brouwer, Andrew; University of Michigan, Ann Arbor, Epidemiology Walline, Heather; University of Michigan, Ann Arbor, Otolaryngology Marinelli, Brittany; University of Michigan, Ann Arbor, Otolaryngology Lau, Yan; University of Michigan, Ann Arbor, Epidemiology Thomas, Trey; University of Michigan, Ann Arbor, Otolaryngology Delinger, Rachel; University of Michigan, Ann Arbor, Epidemiology Sullivan, Taylor; University of Michigan, Ann Arbor, Epidemiology Yost, Monica; University of Michigan, Ann Arbor, Epidemiology Goudsmit, Christine; University of Michigan, Ann Arbor, Otolaryngology Carey, Thomas; University of Michigan, Ann Arbor, Otolaryngology Meza, Rafael; University of Michigan, Epidemiology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology, Infectious diseases, Public health, Sexual health
Keywords:	Human Papillomavirus, Oropharyngeal cancer, Longitudinal study, Sexual behavior, Oral rinse

SCHOLARONE™
Manuscripts

Dynamics and Determinants of HPV Infection from the Michigan HPV and Oropharyngeal Cancer (M-HOC) Study

Marisa C. Eisenberg^{*,†}, Lora P. Campredon[†], Andrew F. Brouwer[†],
Heather M. Walline[‡], Brittany M. Marinelli[‡], Yan Kwan Lau[†], Trey B. Thomas[‡],
Rachel L. Delinger[†], Taylor S. Sullivan[†], Monica L. Yost[†],
Christine M. Goudsmit[‡], Thomas E. Carey[‡], and Rafael Meza^{*,†}

[†] Department of Epidemiology, University of Michigan, Ann Arbor,

[‡] Department of Otolaryngology, University of Michigan, Ann Arbor

* Co-corresponding authors, marisae@umich.edu, rmeza@umich.edu

1415 Washington Heights, 4667 SPH I

Ann Arbor, MI 48109-2029

Phone: (734) 763-2991

Keywords: Human papillomavirus, Sexual behavior, Surveys and questionnaires, Saliva and oral rinse, Cervicovaginal swab

Word count: 3314

Abstract

Introduction: Human papillomavirus (HPV) is the primary cause of cervical and other anogenital cancers, and is also associated with head and neck cancers. Incidence of HPV-related oropharyngeal squamous cell cancers (OPSCCs) is increasing, and HPV-related OPSCCs have surpassed cervical cancer as the most common HPV-related cancer in the U.S. Given the multisite nature of HPV, there is strong interest in collecting data from both genital and oral sites, as well as

1
2
3 associated data on social and sexual behaviors. The overarching goal of this study is to evaluate
4 patterns of oral HPV infection incidence, clearance, and persistence and their relationship to sexual
5 behavior history.
6
7
8

9
10 *Methods and Analysis:* Participants are recruited from two populations: college students at a large
11 public university and general population from the surrounding area. At the first study visit participants
12 will complete a detailed sexual history, health, and behavior questionnaire. Follow-up visits will occur
13 every 3–4 months over 3 years, when participants will complete an abbreviated questionnaire. All
14 participants will provide a saliva sample at each visit, and eligible participants may provide a
15 cervicovaginal self-swab. Genetic material isolated from specimens will be tested for 15 high-risk
16 and 3 low-risk HPV types. Statistical analyses will examine outcome variables including HPV
17 prevalence, incidence, persistence, and clearance. Logistic regression models will be used to
18 estimate odds ratios and 95% confidence intervals for associations between the outcomes of
19 interest and demographic/behavioral variables collected in the questionnaires. The longitudinal HPV
20 infection data and detailed sexual history data collected in the questionnaires will allow us to develop
21 individual-based network models of HPV transmission and will be used to parameterize multi-scale
22 models of HPV-related OPSCC carcinogenesis.
23
24
25
26
27
28
29
30
31
32
33
34
35

36 *Ethics and Dissemination:* This study has been approved by the University of Michigan Institutional
37 Review Board. All participants are consented in person by trained study staff.
38
39
40
41
42
43

44 **Article Summary**

45 **Strengths and Limitations of this study**

- 46
47
48 • Longitudinal design with 3–4 study visits per participant per year allows for analysis of
49 incidence, persistence, and clearance of oral HPV.
50
51
52
53
54
55
56
57
58
59
60

- Collection of both oral and cervicovaginal samples allows for comparison of infections across sites.
- Low prevalence of high-risk oral HPV may limit our ability to connect HPV infection dynamics to demographic, sexual, and behavioral variables.

Introduction

Infectious disease agents account for approximately 20% of cancers worldwide [1]. The human papillomavirus (HPV) is the primary cause of cervical and most anogenital cancers, as well as an increasing fraction of head and neck cancers [2, 3]. Indeed, incidence of HPV-related oropharyngeal squamous cell cancers (OPSCCs) is increasing [4–7], and HPV-related OPSCCs have surpassed cervical cancer as the most common HPV-related cancer in the US [3]. At the University of Michigan Cancer Center, over 80% of OPSCC patients have high-risk HPV detected in their cancers [8]. Although many HPV infections are benign, high-risk HPV infections can disrupt several key cancer regulation pathways, including particularly those involving tumor suppressors p53 and pRb [9, 10].

The underlying reasons behind the significant rise in HPV-related OPSCC rates in the U.S. are unclear. From a prevention perspective, addressing HPV-related OPSCC begins with an understanding of the epidemiology of the virus, both in the oral cavity and more broadly. Estimates from the National Health and Nutrition Examination survey (NHANES) suggest oral HPV prevalence in the U.S. is about 11–12% in men and 3–4 % in women [11–14]. However, while oral HPV infections may clear relatively quickly (the HPV in Men trial estimated a mean clearance time of approximately 7 months [15]), persistent infections may lead to cancer after several decades (although there are no precise estimates of time-to-cancer for OPSCCs, cervical lesions are estimated to progress to cancer in 10–30 years [16]).

1
2
3 While studies are increasingly treating HPV as a multisite disease, the mechanisms underlying
4 the relationship between oral, genital, and anal HPV infections are not understood, although
5 autoinoculation is increasingly implicated [17, 18]. The HPV vaccine further complicates the
6 epidemiological picture: HPV vaccination is expected to have an impact on the rates of oral HPV
7 incidence, at least for those genotypes included in the vaccine [12, 19]. Countries with more
8 aggressive vaccination campaigns, such as Australia, have already seen a reduction in HPV-
9 related genital warts [20, 21]. It remains to be seen whether HPV vaccination will ultimately
10 reduce the incidence and mortality of HPV-related head and neck cancers.
11
12
13
14
15
16
17
18
19

20 Many open questions remain regarding oral HPV transmission, epidemiology, infection and
21 persistence, the mechanisms of HPV-related HN carcinogenesis, and the connection between
22 the ongoing oral HPV epidemic and the rising OPSCC incidence. The knowledge gaps
23 surrounding the mechanisms and epidemiology of HPV in the oral cavity hamper our ability to
24 develop more effective measures to prevent oral HPV infections and, in turn, reduce the burden
25 of head and neck cancers. Prevalence studies can only draw associations between the burden
26 and probable risk factors. Thus, longitudinal studies with frequent testing and assessment of
27 recent sexual behavior are needed to understand HPV transmission, persistence, and clearance
28 and to associate these events with certain behaviors. Here, we describe the methods, study
29 design, and initial study population characteristics of a longitudinal study of oral HPV incidence,
30 clearance, and related sexual behaviors; this study and its cervicovaginal HPV sub-study are
31 the epidemiological arms of the Michigan HPV and Oropharyngeal Cancer (M-HOC) Study. Our
32 research will contribute to a better understanding of the complex factors affecting patterns of
33 HPV infection. This study will inform predictive and mechanistic models and develop effective
34 prevention strategies for OPSCC and other HPV-related cancers.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods and Analysis

Objective

The overarching goal of this study is to evaluate patterns of oral HPV infection incidence and clearance and their relationship to sexual history and sexual behaviors. Participants are recruited to the study from two populations: college students at the University of Michigan (UM) (a large public university) and the general population of the surrounding area. As a secondary goal, we will also compare HPV infection patterns in the oral and cervicovaginal sites as part of a sub-study examining cervicovaginal HPV infection.

Subject enrollment and consent

Here, we describe the process for subject enrollment and consent (diagrammed in Figure 1).

Identification of Study Subjects. Participants are continuously recruited by one of three methods.

1) Advertisement: we place recruitment announcements in UM health clinics and area community sites (e.g. libraries, coffee shops, bus stops), as well as on UM clinical research volunteer's website (www.umclinicalstudies.org). In this method, individuals who are potentially interested in participating in the study contact the study coordinator to determine eligibility. 2)

Screening clinics: we approach participants of the UM health system free throat cancer screening clinic to invite eligible participants to join the study. 3) Student residence halls: once per year, we set up information tables in or near UM residence halls and invite eligible students to join the student.

Eligibility Criteria. Volunteers are considered for enrollment if they

- Are age 18 or older,

- Do not have a history of head or neck cancer,
- Are willing to return for a follow up every 3–4 months over 3 years,
- And are able and willing to provide written informed consent.

To participate in the optional cervicovaginal sub-study, participants must additionally

- Have a vagina,
- Not be pregnant,
- And not be menstruating at the time of the study visit.

Consent. We document informed consent for all willing and eligible participants before enrollment in the study. Separate, additional consent is obtained prior to enrollment in the cervicovaginal sub-study. All study subjects are given the opportunity to consent to storage of residual specimens collected in this study for future research purposes. Specimens collected from subjects who do not consent to specimen banking will be destroyed after completion of the analyses of this study.

Benefit to participants. Since we are not using a clinical test, our IRB approval does not allow returning individual HPV test results to participants, but population-level results will be disseminated through newsletters after peer-reviewed publication. Staff are knowledgeable and available to discuss vaccination and screening with interested participants. Because of the nature of the sexual and behavioral questionnaire, we also have pamphlets for the UM Sexual Assault Prevention and Awareness Center available to participants.

Enrollment and statistical power. Phase I of this study recruited between April 2015 and December 2017, enrolling 395 participants. At this sample size and level of significance 0.05, we will detect the difference at baseline between two equally sized populations with HPV

1
2
3 prevalence 10% and 20% with 80% power. Assuming each participant completes 10 visits, we
4 will detect the difference between 10% and 13% ever HPV positive with more than 80% power.
5
6 At the time of submission, 321 participants had completed at least one follow-up visit, and 1,693
7
8 baseline and follow-up visits had been completed. Follow-up visits are ongoing. Pending
9
10 funding, phase II is anticipated to recruit a similar number of participants (potentially with
11
12 additional study locations as well).
13
14
15
16
17
18
19
20

21 **Figure 1:** Flow diagram for the study detailing recruitment methods, visit structure (baseline and
22 followups), and the cervicovaginal sub-study.
23
24
25
26
27

28 ***Data collection***

29
30
31 We administer surveys and collect biological specimens as described below.
32
33
34

35 *Social and Sexual Behavior Survey.* All study participants complete a comprehensive
36 questionnaire at the baseline visit and an abbreviated questionnaire at all subsequent visits. The
37 questionnaire consists of questions related to demographic information; behavior, including
38 alcohol, cigarette, cigar, tobacco, and other drug use; and sexual practices, sexual history,
39 sexual healthcare (including HPV vaccination status), general health, and history of sexually
40 transmitted infections (STIs). The baseline questionnaire collects a complete sexual history, with
41 subsequent follow up visits providing more recent information and updates. The questions
42 regarding sexual behaviors and history are designed to provide detailed information about the
43 timing of different sexual partnerships and sexual practices in each sexual partnership and form
44 a longitudinal, egocentric sexual network data set. Table 1 details the categories and numbers
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

of questions given in both the baseline and follow-up surveys. The questionnaire is administered electronically via Qualtrics in a quiet, private room. Participants are asked to enter their unique study identification number at the beginning of the questionnaire. Participants are free to skip or otherwise not answer any question.

Table 1: Categories and numbers of questions asked in MHOC study baseline and follow-up questionnaire.

Question category	Number of questions	
	Baseline	Follow-up
Demographic	8	5
Oral health and cancer	5	5
STI testing and diagnosis	17	12
Sexual health and vaccinations	25	16
Sexual behavior	70	6
Sexual partners	22	18
Substance use	20	16

Oral Specimen Collection. Two mL of saliva and oral rinse specimen are collected at each visit (i.e. baseline and every 3-4 months for 3 years) using Oragene RE-100 kits [22]. Participants may use a sweetener or candy to stimulate saliva production if needed.

In the initial phase of the study, we tested several alternative saliva collection methods: Scope-brand mouthwash (administered as in NHANES [23]), and two commercially available kits developed for detection of DNA and RNA in saliva, the OM-505 (suitable for DNA, stable for weeks at room temperature) and RE-100 (designed to protect RNA, stable for 60 days at room temperature) [22, 24]. We were able to detect DNA from saliva in all three methods but were only able to reliably recover RNA from the RE-100 kit sample. We selected the RE-100 kits for use in the study so that we could isolate both DNA and RNA from a single sample.

Cervicovaginal swab collection. Participants fulfilling the eligibility criteria are given the option at each study visit to provide a self-collected cervicovaginal swab sample using a HerSwab [25] in

1
2
3 addition to the oral specimen. The HerSwab is a vaginal swab designed to sample near the
4 cervix. Participants self-administer the swab by inserting the tip of the HerSwab into the vagina;
5 turning the crank so that the brush is fully extended; removing the swab; turning the crank the
6 opposite direction to retract the brush back into the tip; and placing the HerSwab into a provided
7 resealable plastic bag. The participants are provided with the printed, graphical instructions
8 designed by the manufacturer and collect their sample in a restroom. Staff facilitating the study
9 are available to review the procedure and answer any participant questions.
10
11
12
13
14
15
16
17

18 *Cervicovaginal swab acceptability survey.* All study participants who provide a cervicovaginal
19 sample complete a questionnaire after each cervicovaginal self-collection that asks about
20 comfort, ease-of-use, and subjective assessment of the self-collection procedure [26]. The
21 questionnaire is administered electronically via Qualtrics.
22
23
24
25
26
27
28

29 ***Follow-up visit schedule***

30
31
32 Participants are followed for up to three years after their baseline visit, for a total of up to 12
33 study visits. The study prioritizes longitudinal follow-up over regular follow-up, but strives to
34 achieve both. Therefore, if participants miss a follow-up visit, they are not excluded and instead
35 continue the study when next available. This protocol facilitates research in the student
36 population, as students are often gone for extended periods of time on scheduled breaks.
37
38
39
40
41
42
43
44

45 ***Sample processing and analysis***

46
47
48 Sample processing and DNA extraction differs for oral and cervicovaginal samples, but DNA
49 analysis is the same for both kinds of samples.
50
51
52

53 *Oral sample processing.* DNA isolation from saliva samples is performed by first splitting the
54 sample in half, half for DNA and half for RNA. The saliva is heated to 50°C for 60 minutes, 1/25th
55
56
57
58
59
60

1
2
3 volume of prepIT-L2P (DNA Genotek) is added. Sample is incubated for 10 minutes at 4°C and
4
5 spun for 20 minutes at 4100 rpm. After the supernatant is added to equal volumes of 95%
6
7 ethanol to precipitate the DNA. The DNA is pelleted, washed with 200 µL of 70% ethanol and
8
9 dried. The DNA pellet is rehydrated with Tris-EDTA buffer and quantified with picogreen
10
11 (Invitrogen P11496) or the QuBit (Invitrogen Q32850). RNA is isolated from samples that have
12
13 tested positive for HPV DNA. RNA isolation from saliva samples is performed using the
14
15 Oragene RNA isolation method according to the manufacturer's instruction which includes
16
17 QIAgen's RNeasy Micro Kit (74004). In short, the samples are heated to 50°C for 60 minutes,
18
19 95°C for 15 minutes, 20 µL neutralization solution is added. Samples then are incubated on ice
20
21 for 10 minutes followed by the RNeasy Kit protocol. The RNA is then converted to cDNA for
22
23 further testing. The cDNA synthesis is preformed using Invitrogen's Superscript III protocol and
24
25 reagents (18080-044).
26
27

28
29 *Cervicovaginal sample processing.* After collection, the HerSwab is soaked for one minute in 20
30
31 mL of ThinPrep solution and subsequently swished vigorously for one minute. The 20 mL
32
33 solution is then split evenly into two 15 mL nuclease-free conical tubes—one for RNA
34
35 processing and one for DNA—and the tube for RNA is centrifuged. The pellet for RNA use is
36
37 resuspended in RNAlater for isolation and later study. DNA and RNA processing is the same as
38
39 above. For RNA isolation, the cells in RNAlater are pelleted by centrifugation and RNA is
40
41 isolated using the RNeasy as described above. Qiagen reagents are used for DNA isolation.
42
43 The cells in the ThinPrep sample are pelleted, resuspended in cell lysis buffer, incubated with
44
45 Proteinase k, treated with protein precipitation buffer, vortexed vigorously, pelleted and placed
46
47 on ice for 10 minutes. The supernatant is transferred to isopropanol in glycogen solution mixed,
48
49 and the DNA pellet is washed twice with cold ethanol, re-hydrated in hydration solution and
50
51 dissolved at 65°C, and DNA is quantified with picogreen or QuBit.
52
53
54
55
56
57
58
59
60

1
2
3 *DNA analysis.* DNA and cDNA samples are assayed using a previously described, highly-
4 sensitive method [8]. Briefly, multiplex competitive PCR amplification of the heterogeneous E6
5 region of 15 discrete high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73) and 3
6 low-risk (6, 11, 90) HPV types is performed, followed by probe-specific single base extension.
7 Extension products are loaded onto a matrix silicon chip array and separated by size using
8 matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectroscopy,
9 allowing detection of any HPV types present in the sample.
10
11
12
13
14
15
16
17
18
19

20 ***Statistical analysis***

21
22
23 Outcomes of interest include, but are not limited to, HPV prevalence (detection of HPV, or
24 detection of a specific HPV genotype), incidence (detection of HPV in a previously uninfected
25 person, or detection of a specific HPV genotype in a person who previously tested negative for
26 that genotype), persistence (detection of HPV at subsequent study visits, or detection of specific
27 genotypes at subsequent study visits), and clearance (non-detection of HPV in a previously
28 infected person, or non-detection of a specific HPV genotype in a person previously infected by
29 that genotype). Other patterns of HPV detection, such as patterns of intermittent detection of the
30 same genotype or detection of an HPV genotype at the oral site after previous detection at the
31 genital site (or vice versa), will be considered. We will adjust for the time between visits as
32 appropriate. Presence of RNA in addition to DNA will be used to distinguish between active and
33 latent infections.
34
35
36
37
38
39
40
41
42
43
44
45

46
47 Covariates of interest include, but are not limited to, sex, age, student status, HIV-status, sexual
48 orientation, HPV vaccine status, circumcision status, number of vaginal, oral, and anal sexual
49 partners, timing and nature of recent sexual activity, use of sexual protection, and substance
50 use. Demographic and sexual behavior differences among subpopulations will be considered.
51
52
53
54
55
56
57
58
59
60

1
2
3 Logistic regression models will be used to estimate odds ratios and 95% confidence intervals for
4 associations between the outcomes of interest and the demographic/behavioral variables.
5
6 Variables that are significant in univariate analysis or are considered to be relevant based on a
7
8 priori knowledge will be evaluated in multiple logistic regression models. Cox regression models
9
10 will be used to investigate the effect of covariates on clearance. Analyses will be performed in
11
12 SAS or R statistical software.
13
14

15 16 17 **Modeling analysis**

18
19
20
21 The longitudinal HPV infection data and detailed sexual partner and sexual history data
22
23 collected in the questionnaires will allow us to develop individual-based network models of HPV
24
25 transmission. While the data from the study are necessarily egocentric (i.e. we cannot link
26
27 partners reported by participants to any specific individual in or out of the study to form a full
28
29 sexual network), they can nonetheless be used to directly parameterize simulation models of
30
31 transmission. The models we develop can match the timing of partner switching, numbers of
32
33 partners, and type of sexual contact, as well as a range of behavioral and demographic
34
35 covariates as well as HPV infections and clearance times. We will draw from the measured
36
37 distributions and correlation patterns of these variables in our population to generate simulated
38
39 populations with sexual behavior patterns similar to those measured in our study (e.g. using
40
41 approaches based on configuration model methods [27] to connect our simulated sexual
42
43 network based on partner history data). This will allow us to generalize our statistical model
44
45 findings to different populations and to examine counterfactual scenarios of alternative HPV
46
47 vaccine coverage levels. Similar models have been developed for other studies, both for
48
49 sexually transmitted infections and other infectious diseases [28–33]. This study is designed to
50
51 specifically inform such modeling analyses.
52
53
54
55
56
57
58
59
60

Patient and Public Involvement

Patients and the public were not involved in the development of this study. Study results will be disseminated to the public through peer-reviewed publications as described in the ethics and dissemination section. Additionally, the newsletter described below will be made accessible to the public through the study website.

Ethics and dissemination

The MHOC study was approved by the University of Michigan Institutional Review Board on August 26, 2014 (IRB # HUM00090326). This study was deemed to not require additional safety monitoring beyond the monitoring of the institutional review board. All study staff interacting with participants and participant data complete the University of Michigan Program for Education and Evaluation in Responsible Research and Scholarship (PEERRS) prior to beginning the project [31]. Informed consent is obtained from each participant by the study coordinator and PEERRS certified research assistants. Study results will be disseminated through a series of peer-reviewed publications. Study participants will receive a study results newsletter written for a general audience.

Discussion

The knowledge gained from this study will contribute to the field of HPV research, and will be disseminated via peer reviewed publications and presentations at national and international conferences. This study will provide improved estimates of HPV clearance rates in the oral cavity, due to the short follow-up times, and will also allow us to examine how HPV clearance is

1
2
3 affected by a range of factors, including coinfection with multiple HPV types. More broadly, this
4 study will improve our understanding of the relationships between behavior patterns and HPV,
5 helping to elucidate how sexual behaviors, numbers of partners, and other behaviors (e.g.
6 alcohol and substance use) relate to HPV infection patterns. Additionally, this study will provide
7 detailed data on HPV transmission in the college student population—a key population who are
8 also seeing changing vaccination patterns as HPV vaccine coverage improves. This will allow
9 us to further examine the impact of HPV vaccination on the incidence and prevalence of a range
10 of vaccine types (both those covered by the vaccine and others). The study questionnaire and
11 longitudinal design also are also useful in developing sexual network models of transmission,
12 which will allow us to examine alternative vaccination strategies and generalize to other
13 populations.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 ***Limitations and Strengths***

29
30
31 Because oral HPV prevalence in the United States is relatively low (prevalence of high-risk oral
32 HPV among adults 18–69 was 4.0% in 2011–2014: 6.8% in men and 1.2% in women [14]),
33 there is a risk that number of HPV positive samples in the study will be low, limiting our abilities
34 to draw inference between HPV infection and the demographic and behavioral variables of the
35 participant. The quality of our saliva and oral rinse specimens may depend on the saliva
36 production and swishing efficacy of each participant, although this is mitigated by the sensitivity
37 of the PCR analysis. Finally, we only test for 18 genotypes, which, although we cover all high-
38 risk types, may not give as complete a picture of patterns of mucosal HPV infection.
39
40
41
42
43
44
45
46
47
48

49 Instead of identifying risk factors through associations in cross-sectional prevalence analyses,
50 we will use a longitudinal approach with frequent oral and cervicovaginal HPV testing and
51 updated detailed sexual behavior questionnaires. This will allow for understanding not only
52 prevalence of HPV but also incidence, persistence, and clearance. Some studies have also
53
54
55
56
57
58
59
60

1
2
3 adopted a longitudinal approach (e.g. [34–38]), but many have had long times between follow-
4
5 up or have focused only on sex or only on genital infection sites. In the MHOC study, we use
6
7 short follow-up times, with 3–4 visits per participant per year. We focus primarily on oral
8
9 infection in both men and women but also collect cervicovaginal samples to assess multisite
10
11 infections.
12
13
14
15

16 **Author's contributions**

17
18
19 The study was conceptualized and funding was obtained by MCE, TEC, and RM. Methodology
20
21 and original protocols were developed by MCE, LPC, AFB, HMW, BMM, YKL, TBT, RLD, CMG,
22
23 TEC, and RM. Project administration is managed by LPC and YKL. MCE, LPC, AFB, HMW,
24
25 BMM, YKL, CG, TEC, and RM are responsible for supervision of study implementation, staff,
26
27 and students.
28
29
30

31
32 The original draft was prepared by MCE with the assistance of LPC, TSS, and MLY. Review and
33
34 editing was completed by MCE, LPC, AFB, HMW, BMM, YKL, TEC, and RM.
35
36

37 **Funding statement**

38
39
40 This work was supported by National Institutes for Health Grant U01CA182915, the University of
41
42 Michigan MCubed program, a pilot grant from University of Michigan Comprehensive Cancer
43
44 Center's Cancer Epidemiology & Prevention program (supported by the National Cancer
45
46 Institute of the National Institutes of Health grant P30CA046592), and the Michigan Institute for
47
48 Clinical and Health Research (NIH grant UL1TR000433).
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments

We would like to thank Professors Carol Bradford, Paul Hoff, Norm Hogikyan, Trachette Jackson, James Koopman, Kelly Malloy, John McHugh, Erin McKean, Mark Prince, Jamie Riddell, Laura Rozek, Andrew Shuman, Matthew Spector, Jeffrey Stanley, Jeremy Taylor, Francis Worden, and Gregory Wolf, for their helpful comments, advice, and support.

We also thank our collaborators, study and laboratory staff, and students: Miranda West, Thankum Nair, Lisa Petersen, Sheila Terrones, Chad Brenner, Emily Bellile, Justin Bell, Tori Melandez, and Eliyas Asfaw, Christian Alvarez, Kristin Bevilacqua, Pian Pian Cao, Alanna Clark, Jesse Contreras, Rachel Delinger, Greg Foakes, Anna Gottschlich, Manila Hada, Christina Hanson, Nadine Jawad, Bala Naveen Kakaraparthi, Alexandra Kalabat, Jung Woo Lee, Jodi McCloskey, Ivan Montoya, Anna Morris, Chinmay Pandit, Derrick Sund, Kayla Stanek, Peter Tortora, Taylor Vandenberg, and Lucy Yang. We would like to thank all of our staff and our study participants, without whom this study would not have been possible.

Competing interests statement

All authors declare no conflicts of interest.

References

- [1] Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—Part B: biological agents. *The Lancet Oncology*. 2009;10(4):321–322.
- [2] Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine*. 2012 nov;30 Suppl 5:F34–54.
- [3] Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. *Journal of the National Cancer Institute*. 2013;105(3):175–201.
- [4] Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *Journal of Clinical Oncology*. 2008;26(4):612–9.
- [5] Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *Journal of Clinical Oncology*. 2011;29(32):4294–301.
- [6] Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *Journal of Clinical Oncology*. 2013 dec;31(36):4550–9.
- [7] Chaturvedi AK, D'Souza G, Gillison ML, Katki HA. Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. *Oral Oncology*. 2016;60:61–67.

- 1
2
3 [8] Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-Risk
4 Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers.
5 JAMA Otolaryngology–Head & Neck Surgery. 2013;139(12):1320.
6
7
8
9 [9] Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-
10 cycle of human papillomaviruses. *Vaccine*. 2012;30 Suppl 5:F55–70
11
12
13
14 [10] McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papillomaviruses.
15 *Virus Research*. 2009;143(2):195–208.
16
17
18
19 [11] Gillison ML, Broutian T, Pickard RKL, Tong Zy, Xiao W, Kahle L, et al. Prevalence of oral
20 HPV infection in the United States, 2009-2010. *Journal of the American Medical Association*.
21
22
23
24
25
26
27 [12] Brouwer AF, Eisenberg MC, Carey TE, Meza R. Trends in HPV cervical and
28 seroprevalence and associations between oral and genital infection and serum antibodies in
29 NHANES 2003-2012. *BMC Infectious Diseases*. 2015;15(1):575.
30
31
32
33
34 [13] Sonawane K, Suk R, Chiao EY, Chhatwal J, Qiu P, Wilkin T, et al. Oral Human
35 Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With
36 Genital Human Papillomavirus Infection, NHANES 2011 to 2014. *Annals of Internal Medicine*.
37
38
39
40
41
42
43 [14] McQuillan G, Kruszon-moran D, Markowitz LE, Unger ER, Paulose-ram R. Prevalence
44 of HPV in Adults Aged 18–69: United States, 2011–2014. *NCHS Data Brief*. 2017;280.
45
46
47
48 [15] Kreimer AR, Campbell, CMP, Lin H, Fulp W, Papenfuss MR, Abrahamsen M,
49 Hildesheim A, Villa LL, Salmerón JJ, Lazcano-Ponce E, Giuliano AR. Incidence and clearance
50 of oral human papillomavirus infection in men: the HIM cohort study. *The Lancet*.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [16] McCredie M, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DCG.
4
5 Natural history of cervical neoplasia and risk of invasive cancer in women with cervical
6
7 intraepithelial neoplasia 3: a retrospective cohort study. *The Lancet Oncology*. 2008;9(5):425–
8
9 434.
10
11
12 [17] Pamnani SJ, Nyitray AG, Abrahamsen M, Rollison DE, Villa LL, Lazcano-Ponce E, et al.
13
14 Sequential Acquisition of Anal Human Papillomavirus (HPV) Infection Following Genital
15
16 Infection among Men Who Have Sex with Women: The HPV Infection in Men (HIM) Study.
17
18 *Journal of Infectious Diseases*. 2016;214(8):1180–1187.
19
20
21 [18] Ranjeva S, Baskerville EB, Dukic V, Villa L, Lazcano-Ponce E, Giuliano AR, et al.
22
23 Recurring infection with ecologically distinct human papillomavirus (HPV) types explains high
24
25 prevalence and diversity. *bioRxiv*. 2017
26
27
28 [19] Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV
29
30 After Introduction of the Vaccination Program in the United States. *Pediatrics*. 2016;137(3):1–9.
31
32
33 [20] Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich aE, et al. Genital warts in
34
35 young Australians five years into national human papillomavirus vaccination programme:
36
37 national surveillance data. *BMJ*. 2013;346:2032–2032.
38
39
40 [21] Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing
41
42 decline in genital warts among young heterosexuals 7 years after the Australian human
43
44 papillomavirus (HPV) vaccination programme. *Sexually Transmitted Infections*.
45
46 2015;91(3):214–219.
47
48
49 [22] DNA Genotek, Inc. Oragene-RNA (RE-100); 2017. Available from:
50
51 <http://www.dnagenotek.com/US/products/RE100.html>.
52
53
54
55
56
57
58
59
60

1
2
3 [23] Centers for Disease Control and Prevention. National Health and Nutrition Examination
4 Survey (NHANES): HPV rinse; 2009.

5
6
7 Available from: <https://www.cdc.gov/nchs/data/nhanes/2009-2010/manuals/HPV.pdf>.

8
9
10 [24] DNA Genotek, Inc. OMNIgene-ORAL (OM-505); 2017. Available from:
11
12 <http://www.dnagenotek.com/US/products/OM505>.

13
14
15 [25] Eve Medical. Eve Medical products: HerSwab; 2017. Available from: [http://www.eve-](http://www.eve-medical.com/products)
16
17 [medical.com/products](http://www.eve-medical.com/products).

18
19
20 [26] Gottschlich A, Rivera-Andrade A, Grajeda E, Alvarez C, Montano CM, Meza R.
21
22 Acceptability of Human Papillomavirus SelfSampling for Cervical Cancer Screening in an
23
24 Indigenous Community in Guatemala. *Journal of Global Oncology*. 2017;3(5):444– 454.

25
26
27 [27] Newman M. *Networks: An Introduction*. 2010. Oxford University Press.

28
29
30 [28] Petrie JG, Eisenberg MC, Ng S, Malosh RE, Han Lee K, Ohmit SE, et al. Application of
31
32 an Individual-Based Transmission Hazard Model for Estimation of Influenza Vaccine
33
34 Effectiveness in a Household Cohort. *American journal of epidemiology*;

35
36
37 [29] Aiello AE, Simanek AM, Eisenberg MC, Walsh AR, Davis B, Volz E, et al. Design and
38
39 methods of a social network isolation study for reducing respiratory infection transmission: The
40
41 eX-FLU cluster randomized trial. *Epidemics*. 2016;15:38–55.

42
43
44 [30] Fan K, Eisenberg M, Walsh A, Aiello A, Heller K. Hierarchical graph-coupled hmms for
45
46 heterogeneous personalized health data. In: *Proceedings of the 21th ACM SIGKDD*
47
48 *International Conference on Knowledge Discovery and Data Mining*. ACM; 2015. p. 239–248.

49
50
51 [31] Kaplan EH, Heimer R. HIV prevalence among intravenous drug users: model-based
52
53 estimates from New Haven's legal needle exchange. *JAIDS Journal of Acquired Immune*
54
55 *Deficiency Syndromes*. 1992;5(2):163–169.

- 1
2
3 [32] Sloot PM, Ivanov SV, Boukhanovsky AV, van de Vijver DA, Boucher CA. Stochastic
4 simulation of HIV population dynamics through complex network modelling. *International*
5 *Journal of Computer Mathematics*. 2008;85(8):1175–1187.
6
7
8
9
10 [33] Cohen T, Colijn C, Finklea B, Murray M. Exogenous re-infection and the dynamics of
11 tuberculosis epidemics: local effects in a network model of transmission. *Journal of The Royal*
12 *Society Interface*. 2007;4(14):523–531.
13
14
15
16
17 [34] University of Michigan. Responsible Conduct of Research (RCR) Training; 2017.
18 Available from: [http://research-compliance.umich.edu/responsible-conduct-research-rcr-](http://research-compliance.umich.edu/responsible-conduct-research-rcr-training)
19 [training](http://research-compliance.umich.edu/responsible-conduct-research-rcr-training).
20
21
22
23
24 [35] Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal
25 papillomavirus infection in young women. *The New England Journal of Medicine*.
26
27 1998;338(7):423–8.
28
29
30
31 [36] Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, et al. Epidemiology
32 of acquisition and clearance of cervical human papillomavirus infection in women from a high-
33 risk area for cervical cancer. *Journal of Infectious Diseases*. 1999 nov;180(5):1415–23.
34
35
36
37
38 [37] Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al.
39 Determinants of clearance of human papillomavirus infections in Colombian women with normal
40 cytology: a population-based, 5-year follow-up study. *American Journal of Epidemiology*. 2003
41 sep;158(5):486–94.
42
43
44
45
46
47
48 [38] Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al.
49 Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the
50 Hawaii HPV Cohort Study. *The Journal of Infectious Diseases*. 2010;201(9):1331–9.
51
52
53
54
55
56
57
58
59
60




Figure 1: Flow diagram for the study detailing recruitment methods, visit structure (baseline and followups), and the cervicovaginal sub-study.

361x138mm (300 x 300 DPI)

Peer review only

BMJ Open

Dynamics and Determinants of HPV Infection from the Michigan HPV and Oropharyngeal Cancer (M-HOC) Study: Study Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021618.R2
Article Type:	Protocol
Date Submitted by the Author:	01-Aug-2018
Complete List of Authors:	Eisenberg, Marisa; University of Michigan, Ann Arbor, Epidemiology Campredon, Lora; University of Michigan, Ann Arbor, Epidemiology Brouwer, Andrew; University of Michigan, Ann Arbor, Epidemiology Walline, Heather; University of Michigan, Ann Arbor, Otolaryngology Marinelli, Brittany; University of Michigan, Ann Arbor, Otolaryngology Lau, Yan; University of Michigan, Ann Arbor, Epidemiology Thomas, Trey; University of Michigan, Ann Arbor, Otolaryngology Delinger, Rachel; University of Michigan, Ann Arbor, Epidemiology Sullivan, Taylor; University of Michigan, Ann Arbor, Epidemiology Yost, Monica; University of Michigan, Ann Arbor, Epidemiology Goudsmit, Christine; University of Michigan, Ann Arbor, Otolaryngology Carey, Thomas; University of Michigan, Ann Arbor, Otolaryngology Meza, Rafael; University of Michigan, Epidemiology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology, Infectious diseases, Public health, Sexual health
Keywords:	Human Papillomavirus, Oropharyngeal cancer, Longitudinal study, Sexual behavior, Oral rinse

SCHOLARONE™
Manuscripts

Dynamics and Determinants of HPV Infection from the Michigan HPV and Oropharyngeal Cancer (M-HOC) Study: Study Protocol

Marisa C. Eisenberg^{*,†}, Lora P. Campredon[†], Andrew F. Brouwer[†],
Heather M. Walline[‡], Brittany M. Marinelli[‡], Yan Kwan Lau[†], Trey B. Thomas[‡],
Rachel L. Delinger[†], Taylor S. Sullivan[†], Monica L. Yost[†],
Christine M. Goudsmit[‡], Thomas E. Carey[‡], and Rafael Meza^{*,†}

[†] Department of Epidemiology, University of Michigan, Ann Arbor,

[‡] Department of Otolaryngology, University of Michigan, Ann Arbor

* Co-corresponding authors, marisae@umich.edu, rmeza@umich.edu

1415 Washington Heights, 4667 SPH I

Ann Arbor, MI 48109-2029

Phone: (734) 763-2991

Keywords: Human papillomavirus, Sexual behavior, Surveys and questionnaires, Saliva and oral rinse, Cervicovaginal swab

Word count: 3314

Abstract

Introduction: Human papillomavirus (HPV) is the primary cause of cervical and other anogenital cancers and is also associated with head and neck cancers. Incidence of HPV-related oropharyngeal squamous cell cancers (OPSCCs) is increasing, and HPV-related OPSCCs have surpassed cervical cancer as the most common HPV-related cancer in the U.S. Given the multisite nature of HPV, there is strong interest in collecting data from both genital and oral sites, as well as

1
2
3 associated data on social and sexual behaviors. The overarching goal of this study is to evaluate
4 patterns of oral HPV infection incidence, clearance, and persistence and their relationship to sexual
5 behavior history.
6
7
8

9
10 *Methods and Analysis:* Participants are recruited from two populations: college students at a large
11 public university and general population from the surrounding area. At the first study visit participants
12 complete a detailed sexual history, health, and behavior questionnaire. Follow-up visits occur every
13 3–4 months over 3 years, when participants complete an abbreviated questionnaire. All participants
14 provide a saliva sample at each visit, and eligible participants may provide a cervicovaginal self-
15 swab. Genetic material isolated from specimens is tested for 15 high-risk and 3 low-risk HPV types.
16 Statistical analyses will examine outcome variables including HPV prevalence, incidence,
17 persistence, and clearance. Logistic regression models will be used to estimate odds ratios and 95%
18 confidence intervals for associations between the outcomes of interest and demographic/behavioral
19 variables collected in the questionnaires. The longitudinal HPV infection data and detailed sexual
20 history data collected in the questionnaires will allow us to develop individual-based network models
21 of HPV transmission and will be used to parameterize multi-scale models of HPV-related OPSCC
22 carcinogenesis.
23
24
25
26
27
28
29
30
31
32
33
34
35

36 *Ethics and Dissemination:* This study has been approved by the University of Michigan Institutional
37 Review Board. All participants are consented in person by trained study staff. Study results will be
38 disseminated through peer-reviewed publications.
39
40
41
42
43
44
45

46 **Article Summary**

47 **Strengths and Limitations of this study**

- 48 • Longitudinal design with 3–4 study visits per participant per year allows for analysis of
49 incidence, persistence, and clearance of oral HPV.
50
51
52
53
54
55
56
57
58
59
60

- Collection of both oral and cervicovaginal samples allows for comparison of infections across sites.
- Low prevalence of high-risk oral HPV may limit our ability to connect HPV infection dynamics to demographic, sexual, and behavioral variables.
- Participant-dependent saliva production and swishing effectiveness may result in variable sample quality, but this concern is mitigated by PCR sensitivity.
- Our HPV test separately identifies 15 high-risk genotypes but only 3 low-risk genotypes and thus may not provide a complete picture of the patterns of mucosal HPV types.

Introduction

Infectious disease agents account for approximately 20% of cancers worldwide [1]. The human papillomavirus (HPV) is the primary cause of cervical and most anogenital cancers, as well as an increasing fraction of head and neck cancers [2, 3]. Indeed, incidence of HPV-related oropharyngeal squamous cell cancers (OPSCCs) is increasing [4–7], and HPV-related OPSCCs have surpassed cervical cancer as the most common HPV-related cancer in the US [3]. At the University of Michigan Cancer Center, over 80% of OPSCC patients have high-risk HPV detected in their cancers [8]. Although many HPV infections are benign, high-risk HPV infections can disrupt several key cancer regulation pathways, including particularly those involving tumor suppressors p53 and pRb [9, 10].

The underlying reasons behind the significant rise in HPV-related OPSCC rates in the U.S. are unclear. From a prevention perspective, addressing HPV-related OPSCC begins with an understanding of the epidemiology of the virus, both in the oral cavity and more broadly. Estimates from the National Health and Nutrition Examination survey (NHANES) suggest oral HPV prevalence in the U.S. is about 11–12% in men and 3–4 % in women [11–14]. However,

1
2
3 while oral HPV infections may clear relatively quickly (the HPV in Men trial estimated a mean
4 clearance time of approximately 7 months [15]), persistent infections may lead to cancer after
5 several decades (although there are no precise estimates of time-to-cancer for OPSCCs,
6 cervical lesions are estimated to progress to cancer in 10–30 years [16]).
7
8
9

10
11 While studies are increasingly treating HPV as a multisite disease, the mechanisms underlying
12 the relationship between oral, genital, and anal HPV infections are not understood, although
13 autoinoculation is increasingly implicated [17, 18]. The HPV vaccine further complicates the
14 epidemiological picture: HPV vaccination is expected to have an impact on the rates of oral HPV
15 incidence, at least for those genotypes included in the vaccine [12, 19]. Countries with more
16 aggressive vaccination campaigns, such as Australia, have already seen a reduction in HPV-
17 related genital warts [20, 21]. It remains to be seen whether HPV vaccination will ultimately
18 reduce the incidence and mortality of HPV-related head and neck cancers.
19
20
21
22
23
24
25
26
27

28
29 Many open questions remain regarding oral HPV transmission, epidemiology, infection and
30 persistence, the mechanisms of HPV-related HN carcinogenesis, and the connection between
31 the ongoing oral HPV epidemic and the rising OPSCC incidence. The knowledge gaps
32 surrounding the mechanisms and epidemiology of HPV in the oral cavity hamper our ability to
33 develop more effective measures to prevent oral HPV infections and, in turn, reduce the burden
34 of head and neck cancers. Prevalence studies can only draw associations between the burden
35 and probable risk factors. Thus, longitudinal studies with frequent testing and assessment of
36 recent sexual behavior are needed to understand HPV transmission, persistence, and clearance
37 and to associate these events with certain behaviors. Here, we describe the methods, study
38 design, and initial study population characteristics of a longitudinal study of oral HPV incidence,
39 clearance, and related sexual behaviors; this study and its cervicovaginal HPV sub-study are
40 the epidemiological arms of the Michigan HPV and Oropharyngeal Cancer (M-HOC) Study. Our
41 research will contribute to a better understanding of the complex factors affecting patterns of
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 HPV infection. This study will inform predictive and mechanistic models and develop effective
4 prevention strategies for OPSCC and other HPV-related cancers.
5
6
7
8
9

10 **Methods and Analysis**

14 ***Objective***

15
16
17
18 The overarching goal of this study is to evaluate patterns of oral HPV infection incidence and
19 clearance and their relationship to sexual history and sexual behaviors. Participants are
20 recruited to the study from two populations: college students at the University of Michigan (UM)
21 (a large public university) and the general population of the surrounding area. As a secondary
22 goal, we will also compare HPV infection patterns in the oral and cervicovaginal sites as part of
23 a sub-study examining cervicovaginal HPV infection.
24
25
26
27
28
29
30
31

32 ***Subject enrollment and consent***

33
34
35
36 Here, we describe the process for subject enrollment and consent (diagrammed in Figure 1).
37
38

39 *Identification of Study Subjects.* Participants are continuously recruited by one of three methods.
40

41 1) Advertisement: we place recruitment announcements in UM health clinics and area
42 community sites (e.g. libraries, coffee shops, bus stops), as well as on UM clinical research
43 volunteer's website (www.umclinicalstudies.org). In this method, individuals who are potentially
44 interested in participating in the study contact the study coordinator to determine eligibility. 2)
45 Screening clinics: we approach participants of the UM health system free throat cancer
46 screening clinic to invite eligible participants to join the study. 3) Student residence halls: once
47
48
49
50
51
52
53
54
55
56
57
58
59
60

per year, we set up information tables in or near UM residence halls and invite eligible students to join the student.

Eligibility Criteria. Volunteers are considered for enrollment if they

- Are age 18 or older,
- Do not have a history of head or neck cancer,
- Are willing to return for a follow up every 3–4 months over 3 years,
- And are able and willing to provide written informed consent.

To participate in the optional cervicovaginal sub-study, participants must additionally

- Have a vagina,
- Not be pregnant,
- And not be menstruating at the time of the study visit.

Consent. We document informed consent for all willing and eligible participants before enrollment in the study. Separate, additional consent is obtained prior to enrollment in the cervicovaginal sub-study. All study subjects are given the opportunity to consent to storage of residual specimens collected in this study for future research purposes. Specimens collected from subjects who do not consent to specimen banking will be destroyed after completion of the analyses of this study.

Benefit to participants. Since we are not using a clinical test, our IRB approval does not allow returning individual HPV test results to participants, but population-level results will be disseminated through newsletters after peer-reviewed publication. Staff are knowledgeable and available to discuss vaccination and screening with interested participants. Because of the

1
2
3 nature of the sexual and behavioral questionnaire, we also have pamphlets for the UM Sexual
4 Assault Prevention and Awareness Center available to participants.
5

6
7
8 *Enrollment and statistical power.* Phase I of this study recruited between April 2015 and
9 December 2017, enrolling 395 participants. At this sample size and level of significance 0.05,
10 we will detect the difference at baseline between two equally sized populations with HPV
11 prevalence 10% and 20% with 80% power. Assuming each participant completes 10 visits, we
12 will detect the difference between 10% and 13% ever HPV positive with more than 80% power.
13
14 At the time of submission, 321 participants had completed at least one follow-up visit, and 1,693
15 baseline and follow-up visits had been completed. Follow-up visits are ongoing. Pending
16 funding, phase II is anticipated to recruit a similar number of participants (potentially with
17 additional study locations as well).
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 **Figure 1:** Flow diagram for the study detailing recruitment methods, visit structure (baseline and
33 follow-ups), and the cervicovaginal sub-study.
34
35
36
37
38
39
40
41
42

43 **Data collection**

44 We administer surveys and collect biological specimens as described below.
45

46 *Social and Sexual Behavior Survey.* All study participants complete a comprehensive
47 questionnaire at the baseline visit and an abbreviated questionnaire at all subsequent visits. The
48 questionnaire consists of questions related to demographic information; behavior, including
49 alcohol, cigarette, cigar, tobacco, and other drug use; and sexual practices, sexual history,
50 sexual healthcare (including HPV vaccination status), general health, and history of sexually
51
52
53
54
55
56
57
58
59
60

transmitted infections (STIs). The baseline questionnaire collects a complete sexual history, with subsequent follow up visits providing more recent information and updates. The questions regarding sexual behaviors and history are designed to provide detailed information about the timing of different sexual partnerships and sexual practices in each sexual partnership and form a longitudinal, egocentric sexual network data set. Table 1 details the categories and numbers of questions given in both the baseline and follow-up surveys. The questionnaire is administered electronically via Qualtrics in a quiet, private room. Participants are asked to enter their unique study identification number at the beginning of the questionnaire. Participants are free to skip or otherwise not answer any question.

Table 1: Categories and numbers of questions asked in MHOC study baseline and follow-up questionnaire.

Question category	Number of questions	
	Baseline	Follow-up
Demographic	8	5
Oral health and cancer	5	5
STI testing and diagnosis	17	12
Sexual health and vaccinations	25	16
Sexual behavior	70	6
Sexual partners	22	18
Substance use	20	16

Oral Specimen Collection. Two mL of saliva and oral rinse specimen are collected at each visit (i.e. baseline and every 3-4 months for 3 years) using Oragene RE-100 kits [22]. Participants may use a sweetener or candy to stimulate saliva production if needed.

In the initial phase of the study, we tested several alternative saliva collection methods: Scope-brand mouthwash (administered as in NHANES [23]), and two commercially available kits developed for detection of DNA and RNA in saliva, the OM-505 (suitable for DNA, stable for weeks at room temperature) and RE-100 (designed to protect RNA, stable for 60 days at room

1
2
3 temperature) [22, 24]. We were able to detect DNA from saliva in all three methods but were
4 only able to reliably recover RNA from the RE-100 kit sample. We selected the RE-100 kits for
5 use in the study so that we could isolate both DNA and RNA from a single sample.
6
7

8
9
10 *Cervicovaginal swab collection.* Participants fulfilling the eligibility criteria are given the option at
11 each study visit to provide a self-collected cervicovaginal swab sample using a HerSwab [25] in
12 addition to the oral specimen. The HerSwab is a vaginal swab designed to sample near the
13 cervix. Participants self-administer the swab by inserting the tip of the HerSwab into the vagina;
14 turning the crank so that the brush is fully extended; removing the swab; turning the crank the
15 opposite direction to retract the brush back into the tip; and placing the HerSwab into a provided
16 resealable plastic bag. The participants are provided with the printed, graphical instructions
17 designed by the manufacturer and collect their sample in a restroom. Staff facilitating the study
18 are available to review the procedure and answer any participant questions.
19
20
21
22
23
24
25
26
27
28

29 *Cervicovaginal swab acceptability survey.* All study participants who provide a cervicovaginal
30 sample complete a questionnaire after each cervicovaginal self-collection that asks about
31 comfort, ease-of-use, and subjective assessment of the self-collection procedure [26]. The
32 questionnaire is administered electronically via Qualtrics.
33
34
35
36
37
38
39

40 ***Follow-up visit schedule***

41
42
43 Participants are followed for up to three years after their baseline visit, for a total of up to 12
44 study visits. The study prioritizes longitudinal follow-up over regular follow-up, but strives to
45 achieve both. Therefore, if participants miss a follow-up visit, they are not excluded and instead
46 continue the study when next available. This protocol facilitates research in the student
47 population, as students are often gone for extended periods of time on scheduled breaks.
48
49
50
51
52
53
54
55
56
57
58
59
60

Sample processing and analysis

Sample processing and DNA extraction differs for oral and cervicovaginal samples, but DNA analysis is the same for both kinds of samples.

Oral sample processing. DNA isolation from saliva samples is performed by first splitting the sample in half, half for DNA and half for RNA. The saliva is heated to 50°C for 60 minutes, 1/25th volume of prepIT-L2P (DNA Genotek) is added. Sample is incubated for 10 minutes at 4°C and spun for 20 minutes at 4100 rpm. After the supernatant is added to equal volumes of 95% ethanol to precipitate the DNA. The DNA is pelleted, washed with 200 µL of 70% ethanol and dried. The DNA pellet is rehydrated with Tris-EDTA buffer and quantified with picogreen (Invitrogen P11496) or the QuBit (Invitrogen Q32850). RNA is isolated from samples that have tested positive for HPV DNA. RNA isolation from saliva samples is performed using the Oragene RNA isolation method according to the manufacturer's instruction which includes QIAgen's RNeasy Micro Kit (74004). In short, the samples are heated to 50°C for 60 minutes, 95°C for 15 minutes, 20 µL neutralization solution is added. Samples then are incubated on ice for 10 minutes followed by the RNeasy Kit protocol. The RNA is then converted to cDNA for further testing. The cDNA synthesis is preformed using Invitrogen's Superscript III protocol and reagents (18080-044).

Cervicovaginal sample processing. After collection, the HerSwab is soaked for one minute in 20 mL of ThinPrep solution and subsequently swished vigorously for one minute. The 20 mL solution is then split evenly into two 15 mL nuclease-free conical tubes—one for RNA processing and one for DNA—and the tube for RNA is centrifuged. The pellet for RNA use is resuspended in RNAlater for isolation and later study. DNA and RNA processing is the same as above. For RNA isolation, the cells in RNAlater are pelleted by centrifugation and RNA is isolated using the RNeasy as described above. Qiagen reagents are used for DNA isolation.

1
2
3 The cells in the ThinPrep sample are pelleted, resuspended in cell lysis buffer, incubated with
4 Proteinase k, treated with protein precipitation buffer, vortexed vigorously, pelleted and placed
5 on ice for 10 minutes. The supernatant is transferred to isopropanol in glycogen solution mixed,
6 and the DNA pellet is washed twice with cold ethanol, re-hydrated in hydration solution and
7 dissolved at 65°C, and DNA is quantified with picogreen or QuBit.
8
9

10
11
12
13
14 *DNA analysis.* DNA and cDNA samples are assayed using a previously described, highly-
15 sensitive method [8]. Briefly, multiplex competitive PCR amplification of the heterogeneous E6
16 region of 15 discrete high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73) and 3
17 low-risk (6, 11, 90) HPV types is performed, followed by probe-specific single base extension.
18 Extension products are loaded onto a matrix silicon chip array and separated by size using
19 matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectroscopy,
20 allowing detection of any HPV types present in the sample.
21
22
23
24
25
26
27
28
29
30

31 ***Statistical analysis***

32
33
34 Outcomes of interest include, but are not limited to, HPV prevalence (detection of HPV, or
35 detection of a specific HPV genotype), incidence (detection of HPV in a previously uninfected
36 person, or detection of a specific HPV genotype in a person who previously tested negative for
37 that genotype), persistence (detection of HPV at subsequent study visits, or detection of specific
38 genotypes at subsequent study visits), and clearance (non-detection of HPV in a previously
39 infected person, or non-detection of a specific HPV genotype in a person previously infected by
40 that genotype). Other patterns of HPV detection, such as patterns of intermittent detection of the
41 same genotype or detection of an HPV genotype at the oral site after previous detection at the
42 genital site (or vice versa), will be considered. We will adjust for the time between visits as
43 appropriate. Presence of RNA in addition to DNA will be used to distinguish between active and
44 latent infections.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Covariates of interest include, but are not limited to, sex, age, student status, HIV-status, sexual
4 orientation, HPV vaccine status, circumcision status, number of vaginal, oral, and anal sexual
5 partners, timing and nature of recent sexual activity, use of sexual protection, and substance
6 use. Demographic and sexual behavior differences among subpopulations will be considered.
7
8
9

10
11
12 Logistic regression models will be used to estimate odds ratios and 95% confidence intervals for
13 associations between the outcomes of interest and the demographic/behavioral variables.
14 Variables that are significant in univariate analysis or are considered to be relevant based on a
15 priori knowledge will be evaluated in multiple logistic regression models. Cox regression models
16 will be used to investigate the effect of covariates on clearance. Analyses will be performed in
17 SAS or R statistical software.
18
19
20
21
22
23
24
25
26

27 ***Modeling analysis***

28
29
30 The longitudinal HPV infection data and detailed sexual partner and sexual history data
31 collected in the questionnaires will allow us to develop individual-based network models of HPV
32 transmission. While the data from the study are necessarily egocentric (i.e. we cannot link
33 partners reported by participants to any specific individual in or out of the study to form a full
34 sexual network), they can nonetheless be used to directly parameterize simulation models of
35 transmission. The models we develop can match the timing of partner switching, numbers of
36 partners, and type of sexual contact, as well as a range of behavioral and demographic
37 covariates as well as HPV infections and clearance times. We will draw from the measured
38 distributions and correlation patterns of these variables in our population to generate simulated
39 populations with sexual behavior patterns similar to those measured in our study (e.g. using
40 approaches based on configuration model methods [27] to connect our simulated sexual
41 network based on partner history data). This will allow us to generalize our statistical model
42 findings to different populations and to examine counterfactual scenarios of alternative HPV
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 vaccine coverage levels. Similar models have been developed for other studies, both for
4 sexually transmitted infections and other infectious diseases [28–33]. This study is designed to
5 specifically inform such modeling analyses.
6
7
8
9
10

11 ***Patient and Public Involvement***

12
13
14
15 Patients and the public were not involved in the development of this study. Study results will be
16 disseminated to the public through peer-reviewed publications as described in the ethics and
17 dissemination section. Additionally, the newsletter described below will be made accessible to
18 the public through the study website.
19
20
21
22
23
24
25

26 **Ethics and dissemination**

27
28
29
30
31 The MHOC study was approved by the University of Michigan Institutional Review Board on
32 August 26, 2014 (IRB # HUM00090326). This study was deemed to not require additional safety
33 monitoring beyond the monitoring of the institutional review board. All study staff interacting with
34 participants and participant data complete the University of Michigan Program for Education and
35 Evaluation in Responsible Research and Scholarship (PEERRS) prior to beginning the project
36 [31]. Informed consent is obtained from each participant by the study coordinator and PEERRS
37 certified research assistants. Study results will be disseminated through a series of peer-
38 reviewed publications. Study participants will receive a study results newsletter written for a
39 general audience.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

The knowledge gained from this study will contribute to the field of HPV research and will be disseminated via peer reviewed publications and presentations at national and international conferences. This study will provide improved estimates of HPV clearance rates in the oral cavity, due to the short follow-up times, and will also allow us to examine how HPV clearance is affected by a range of factors, including coinfection with multiple HPV types. More broadly, this study will improve our understanding of the relationships between behavior patterns and HPV, helping to elucidate how sexual behaviors, numbers of partners, and other behaviors (e.g. alcohol and substance use) relate to HPV infection patterns. Additionally, this study will provide detailed data on HPV transmission in the college student population—a key population who are also seeing changing vaccination patterns as HPV vaccine coverage improves. This will allow us to further examine the impact of HPV vaccination on the incidence and prevalence of a range of vaccine types (both those covered by the vaccine and others). The study questionnaire and longitudinal design also are also useful in developing sexual network models of transmission, which will allow us to examine alternative vaccination strategies and generalize to other populations.

Limitations and Strengths

Because oral HPV prevalence in the United States is relatively low (prevalence of high-risk oral HPV among adults 18–69 was 4.0% in 2011–2014: 6.8% in men and 1.2% in women [14]), there is a risk that number of HPV positive samples in the study will be low, limiting our abilities to draw inference between HPV infection and the demographic and behavioral variables of the participant. The quality of our saliva and oral rinse specimens may depend on the saliva production and swishing efficacy of each participant, although this is mitigated by the sensitivity

1
2
3 of the PCR analysis. Finally, we only test for 18 genotypes, which, although we cover all high-
4 risk types, may not give as complete a picture of patterns of mucosal HPV infection.
5

6
7
8 Instead of identifying risk factors through associations in cross-sectional prevalence analyses,
9
10 we will use a longitudinal approach with frequent oral and cervicovaginal HPV testing and
11
12 updated detailed sexual behavior questionnaires. This will allow for understanding not only
13
14 prevalence of HPV but also incidence, persistence, and clearance. Some studies have also
15
16 adopted a longitudinal approach (e.g. [34–38]), but many have had long times between follow-
17
18 up or have focused only on sex or only on genital infection sites. In the MHOC study, we use
19
20 short follow-up times, with 3–4 visits per participant per year. We focus primarily on oral
21
22 infection in both men and women but also collect cervicovaginal samples to assess multisite
23
24 infections.
25

26 27 28 29 **Author's contributions**

30
31
32
33 The study was conceptualized and funding was obtained by MCE, TEC, and RM. Methodology
34
35 and original protocols were developed by MCE, LPC, AFB, HMW, BMM, YKL, TBT, RLD, CMG,
36
37 TEC, and RM. Project administration is managed by LPC and YKL. MCE, LPC, AFB, HMW,
38
39 BMM, YKL, CG, TEC, and RM are responsible for supervision of study implementation, staff,
40
41 and students. The original draft was prepared by MCE with the assistance of LPC, TSS, and
42
43 MLY. Review and editing was completed by MCE, LPC, AFB, HMW, BMM, YKL, TEC, and RM.
44
45

46 47 **Funding statement**

48
49
50 This work was supported by National Institutes for Health Grant U01CA182915, the University of
51
52 Michigan MCubed program, a pilot grant from University of Michigan Comprehensive Cancer
53
54 Center's Cancer Epidemiology & Prevention program (supported by the National Cancer
55
56
57

1
2
3 Institute of the National Institutes of Health grant P30CA046592), and the Michigan Institute for
4
5 Clinical and Health Research (NIH grant UL1TR000433).
6
7

8 9 **Acknowledgments**

10
11
12 We would like to thank Professors Carol Bradford, Paul Hoff, Norm Hogikyan, Trachette
13
14 Jackson, James Koopman, Kelly Malloy, John McHugh, Erin McKean, Mark Prince, Jamie
15
16 Riddell, Laura Rozek, Andrew Shuman, Matthew Spector, Jeffrey Stanley, Jeremy Taylor,
17
18 Francis Worden, and Gregory Wolf, for their helpful comments, advice, and support.
19

20
21 We also thank our collaborators, study and laboratory staff, and students: Miranda West,
22
23 Thankum Nair, Lisa Petersen, Sheila Terrones, Chad Brenner, Emily Bellile, Justin Bell, Tori
24
25 Melandez, and Eliyas Asfaw, Christian Alvarez, Kristin Bevilacqua, Pian Pian Cao, Alanna
26
27 Clark, Jesse Contreras, Rachel Delinger, Greg Foakes, Anna Gottschlich, Manila Hada,
28
29 Christina Hanson, Nadine Jawad, Bala Naveen Kakaraparthi, Alexandra Kalabat, Jung Woo
30
31 Lee, Jodi McCloskey, Ivan Montoya, Anna Morris, Chinmay Pandit, Derrick Sund, Kayla Stanek,
32
33 Peter Tortora, Taylor Vandenberg, and Lucy Yang. We would like to thank all of our staff and
34
35 our study participants, without whom this study would not have been possible.
36
37
38

39 **Competing interests statement**

40
41
42
43 All authors declare no conflicts of interest.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- [1] Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—Part B: biological agents. *The Lancet Oncology*. 2009;10(4):321–322.
- [2] Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine*. 2012 nov;30 Suppl 5:F34–54.
- [3] Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. *Journal of the National Cancer Institute*. 2013;105(3):175–201.
- [4] Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *Journal of Clinical Oncology*. 2008;26(4):612–9.
- [5] Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *Journal of Clinical Oncology*. 2011;29(32):4294–301.
- [6] Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *Journal of Clinical Oncology*. 2013 dec;31(36):4550–9.
- [7] Chaturvedi AK, D'Souza G, Gillison ML, Katki HA. Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. *Oral Oncology*. 2016;60:61–67.

- 1
2
3 [8] Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-Risk
4 Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers.
5 JAMA Otolaryngology–Head & Neck Surgery. 2013;139(12):1320.
6
7
8
9 [9] Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-
10 cycle of human papillomaviruses. *Vaccine*. 2012;30 Suppl 5:F55–70
11
12
13
14 [10] McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papillomaviruses.
15 *Virus Research*. 2009;143(2):195–208.
16
17
18
19 [11] Gillison ML, Broutian T, Pickard RKL, Tong Zy, Xiao W, Kahle L, et al. Prevalence of oral
20 HPV infection in the United States, 2009-2010. *Journal of the American Medical Association*.
21
22 2012;307(7):693–703.
23
24
25
26 [12] Brouwer AF, Eisenberg MC, Carey TE, Meza R. Trends in HPV cervical and
27 seroprevalence and associations between oral and genital infection and serum antibodies in
28 NHANES 2003-2012. *BMC Infectious Diseases*. 2015;15(1):575.
29
30
31
32 [13] Sonawane K, Suk R, Chiao EY, Chhatwal J, Qiu P, Wilkin T, et al. Oral Human
33 Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With
34 Genital Human Papillomavirus Infection, NHANES 2011 to 2014. *Annals of Internal Medicine*.
35
36 2017; 167(10):714-724.
37
38
39
40 [14] McQuillan G, Kruszon-moran D, Markowitz LE, Unger ER, Paulose-ram R. Prevalence
41 of HPV in Adults Aged 18–69: United States, 2011–2014. *NCHS Data Brief*. 2017;280.
42
43
44
45 [15] Kreimer AR, Campbell, CMP, Lin H, Fulp W, Papenfuss MR, Abrahamsen M,
46 Hildesheim A, Villa LL, Salmerón JJ, Lazcano-Ponce E, Giuliano AR. Incidence and clearance
47 of oral human papillomavirus infection in men: the HIM cohort study. *The Lancet*.
48 2013;382(9895):877–887.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [16] McCredie M, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DCG.
4
5 Natural history of cervical neoplasia and risk of invasive cancer in women with cervical
6
7 intraepithelial neoplasia 3: a retrospective cohort study. *The Lancet Oncology*. 2008;9(5):425–
8
9 434.
10
11
12 [17] Pamnani SJ, Nyitray AG, Abrahamsen M, Rollison DE, Villa LL, Lazcano-Ponce E, et al.
13
14 Sequential Acquisition of Anal Human Papillomavirus (HPV) Infection Following Genital
15
16 Infection among Men Who Have Sex with Women: The HPV Infection in Men (HIM) Study.
17
18 *Journal of Infectious Diseases*. 2016;214(8):1180–1187.
19
20
21 [18] Ranjeva S, Baskerville EB, Dukic V, Villa L, Lazcano-Ponce E, Giuliano AR, et al.
22
23 Recurring infection with ecologically distinct human papillomavirus (HPV) types explains high
24
25 prevalence and diversity. *bioRxiv*. 2017
26
27
28 [19] Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV
29
30 After Introduction of the Vaccination Program in the United States. *Pediatrics*. 2016;137(3):1–9.
31
32
33 [20] Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich aE, et al. Genital warts in
34
35 young Australians five years into national human papillomavirus vaccination programme:
36
37 national surveillance data. *BMJ*. 2013;346:2032–2032.
38
39
40 [21] Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing
41
42 decline in genital warts among young heterosexuals 7 years after the Australian human
43
44 papillomavirus (HPV) vaccination programme. *Sexually Transmitted Infections*.
45
46 2015;91(3):214–219.
47
48
49 [22] DNA Genotek, Inc. Oragene-RNA (RE-100); 2017. Available from:
50
51 <http://www.dnagenotek.com/US/products/RE100.html>.
52
53
54
55
56
57
58
59
60

1
2
3 [23] Centers for Disease Control and Prevention. National Health and Nutrition Examination
4 Survey (NHANES): HPV rinse; 2009.

5
6
7 Available from: <https://www.cdc.gov/nchs/data/nhanes/2009-2010/manuals/HPV.pdf>.

8
9
10 [24] DNA Genotek, Inc. OMNIgene-ORAL (OM-505); 2017. Available from:
11
12 <http://www.dnagenotek.com/US/products/OM505>.

13
14
15 [25] Eve Medical. Eve Medical products: HerSwab; 2017. Available from: [http://www.eve-](http://www.eve-medical.com/products)
16
17 [medical.com/products](http://www.eve-medical.com/products).

18
19
20 [26] Gottschlich A, Rivera-Andrade A, Grajeda E, Alvarez C, Montano CM, Meza R.
21
22 Acceptability of Human Papillomavirus SelfSampling for Cervical Cancer Screening in an
23
24 Indigenous Community in Guatemala. *Journal of Global Oncology*. 2017;3(5):444– 454.

25
26
27 [27] Newman M. *Networks: An Introduction*. 2010. Oxford University Press.

28
29
30 [28] Petrie JG, Eisenberg MC, Ng S, Malosh RE, Han Lee K, Ohmit SE, et al. Application of
31
32 an Individual-Based Transmission Hazard Model for Estimation of Influenza Vaccine
33
34 Effectiveness in a Household Cohort. *American journal of epidemiology*;

35
36
37 [29] Aiello AE, Simanek AM, Eisenberg MC, Walsh AR, Davis B, Volz E, et al. Design and
38
39 methods of a social network isolation study for reducing respiratory infection transmission: The
40
41 eX-FLU cluster randomized trial. *Epidemics*. 2016;15:38–55.

42
43
44 [30] Fan K, Eisenberg M, Walsh A, Aiello A, Heller K. Hierarchical graph-coupled hmms for
45
46 heterogeneous personalized health data. In: *Proceedings of the 21th ACM SIGKDD*
47
48 *International Conference on Knowledge Discovery and Data Mining*. ACM; 2015. p. 239–248.

49
50
51 [31] Kaplan EH, Heimer R. HIV prevalence among intravenous drug users: model-based
52
53 estimates from New Haven's legal needle exchange. *JAIDS Journal of Acquired Immune*
54
55 *Deficiency Syndromes*. 1992;5(2):163–169.

1
2
3 [32] Sloot PM, Ivanov SV, Boukhanovsky AV, van de Vijver DA, Boucher CA. Stochastic
4 simulation of HIV population dynamics through complex network modelling. *International*
5 *Journal of Computer Mathematics*. 2008;85(8):1175–1187.
6
7

8
9
10 [33] Cohen T, Colijn C, Finklea B, Murray M. Exogenous re-infection and the dynamics of
11 tuberculosis epidemics: local effects in a network model of transmission. *Journal of The Royal*
12 *Society Interface*. 2007;4(14):523–531.
13
14

15
16
17 [34] University of Michigan. Responsible Conduct of Research (RCR) Training; 2017.
18 Available from: [http://research-compliance.umich.edu/responsible-conduct-research-rcr-](http://research-compliance.umich.edu/responsible-conduct-research-rcr-training)
19 [training](http://research-compliance.umich.edu/responsible-conduct-research-rcr-training).
20
21

22
23
24 [35] Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal
25 papillomavirus infection in young women. *The New England Journal of Medicine*.
26
27 1998;338(7):423–8.
28
29

30
31 [36] Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, et al. Epidemiology
32 of acquisition and clearance of cervical human papillomavirus infection in women from a high-
33 risk area for cervical cancer. *Journal of Infectious Diseases*. 1999 nov;180(5):1415–23.
34
35

36
37
38 [37] Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al.
39 Determinants of clearance of human papillomavirus infections in Colombian women with normal
40 cytology: a population-based, 5-year follow-up study. *American Journal of Epidemiology*. 2003
41 sep;158(5):486–94.
42
43
44

45
46
47 [38] Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al.
48 Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the
49 Hawaii HPV Cohort Study. *The Journal of Infectious Diseases*. 2010;201(9):1331–9.
50
51
52
53




Figure 1: Flow diagram for the study detailing recruitment methods, visit structure (baseline and followups), and the cervicovaginal sub-study.

361x138mm (300 x 300 DPI)

Peer review only